FCGR3A gene modified non-human animal
A genetically modified animal model expressing human FCGR3A protein addresses the limitations of traditional drug development by replicating human disease environments, improving drug screening and evaluation efficiency and reducing costs.
Patent Information
- Application Number
- CN202411463843.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-06
- Filing Date
- 2024-10-18
- Publication Date
- 2024-12-03
AI Technical Summary
Traditional drug development methods using in vitro and in vivo animal models fail to replicate human body environments, leading to high failure rates and discrepancies between animal test results and clinical trials due to the lack of tumor microenvironment and immune cell interactions.
Development of a genetically modified non-human animal model expressing human or humanized FCGR3A protein, constructed by replacing the endogenous FCGR4 locus with a nucleotide sequence encoding human or humanized FCGR3A, allowing for regulated expression and functional mimicry of human FCGR3A.
The model provides a powerful tool for studying FCGR3A function and screening drugs, reducing development costs and time by simulating human disease conditions and immune interactions, enhancing drug efficacy and safety testing.
Smart Images

Figure CN119061071A_ABST
Abstract
Description
Technical Field
[0001] The present invention provides a non-human animal expressing a human or humanized (eg, humanized) FCGR3A protein and methods of using the same. Background Art
[0002] Traditional drug development usually uses in vitro screening methods, but these screening methods cannot provide the body environment (such as tumor microenvironment, stromal cells, extracellular matrix components and immune cell interactions, etc.), resulting in a high failure rate of drug development. In addition, given the differences between humans and animals, the test results obtained from in vivo pharmacology tests using conventional experimental animals may not reflect the actual disease state and the interaction of the target site, resulting in significant differences between the results of many clinical trials and the results of animal experiments.
[0003] Therefore, developing a humanized animal model suitable for screening and evaluation of human antibodies will significantly improve the efficiency of new drug development and reduce the cost of drug development.
[0004] However, the construction of humanized animal models is very difficult. For example, the non-patent literature: Generation and utility of genetically humanized mouse models (Scheer N, Snaith M, Wolf CR, Seib1er J., Drug Discovery Today; 18(23-24): 1200-11, 2013) discloses that the humanization of any gene carries certain risks, and even with carefully designed strategies, the expression and function of human genes in animals cannot be ensured. Summary of the invention
[0005] The present application provides an animal model with human or humanized FCGR3A protein. The animal model can express human or humanized FCGR3A (e.g., humanized FCGR3A) protein. It can be used for the study of FCGR3A gene function, and can also be used for the screening and evaluation of FCGR3A signaling pathway regulators (e.g., anti-FCGR3A antibodies, oligonucleotide drugs and / or polypeptide drugs). In addition, the animal model prepared by the method described in the present application can be used for drug screening, pharmacodynamics research, treatment of immune diseases and treatment of diseases at human FCGR3A target sites; the model can also be used to promote new drug development and design, saving time and cost. In summary, the present invention provides a powerful tool for studying the function of FCGR3A protein and provides a platform for screening related drugs.
[0006] In one aspect, the present invention provides a genetically modified non-human animal or a method for constructing the same, wherein the genome of the non-human animal comprises at least one chromosome, wherein the chromosome comprises a nucleotide sequence encoding a human or humanized Fcγ receptor IIIa (FCGR3A) protein. In some embodiments, the nucleotide sequence encoding the human or humanized FCGR3A protein is operably linked to a regulatory element of an endogenous FCGR4 locus of at least one chromosome (e.g., a promoter, 5'UTR and / or 3'UTR endogenous to a human or non-human animal). In some embodiments, the expression of the nucleotide sequence encoding the human or humanized FCGR3A protein is regulated by a regulatory element, and the regulatory element is preferably a regulatory element endogenous to a human or non-human animal (e.g., a promoter, 5'UTR and / or 3'UTR endogenous to a human or non-human animal). In some embodiments, the humanized FCGR3A protein comprises a human or humanized extracellular region, a human or humanized transmembrane region and a cytoplasmic region of a non-human animal. In some embodiments, the humanized FCGR3A protein further comprises a signal peptide of a human or non-human animal. In some embodiments, the amino acid sequence of the human or humanized FCGR3A protein comprises SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229. In some embodiments, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 1 or SEQ ID NO: 1 positions 225-249; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to SEQ ID NO: 1 or SEQ ID NO: 1 positions 225-249. In some embodiments, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 7 or SEQ ID NO: 33; or, comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to SEQ ID NO: 7 or SEQ ID NO: 33. In some embodiments, the non-human animal comprises a mammal, such as a monkey or a rodent. In some embodiments, the rodent comprises a mouse or a rat. In some embodiments, the non-human animal is a mouse. In some embodiments, the endogenous FCGR4 protein of the non-human animal is not expressed or is expressed at a reduced level compared to FCGR4 in wild-type animals. In some embodiments, one or more cells of the non-human animal express the human or humanized FCGR3A protein.
[0007] On the one hand, the present invention provides a genetically modified non-human animal or a method for constructing it, wherein the endogenous FCGR4 gene of the non-human animal is replaced with a nucleotide sequence comprising human or humanized FCGR3A at the endogenous FCGR4 locus of the non-human animal. In some embodiments, all or part of exons 1-5 of the endogenous FCGR4 gene of the non-human animal are replaced. In some embodiments, the replaced endogenous FCGR4 gene of the non-human animal also comprises at least 50bp of continuous nucleotide sequence upstream of the 5'UTR and / or at least 50bp of continuous nucleotide sequence downstream of the 3'UTR of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the replaced endogenous FCGR4 gene of the non-human animal comprises at least 6764bp upstream of the endogenous 5'UTR, and preferably, the nucleotide sequence also comprises at least 872bp of continuous nucleotides downstream of the endogenous 3'UTR. In some embodiments, one or more cells of the non-human animal express human or humanized FCGR3A, and the human or humanized FCGR3A comprises an extracellular region, a transmembrane region and a cytoplasmic region, and the extracellular region and / or transmembrane region are consistent with or have an identity of at least 50%, 60%, 70%, 80%, 90%, 95% or 99% with the extracellular region and / or transmembrane region of human FCGR3A. In some embodiments, the extracellular region and / or transmembrane region are consistent with at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 consecutive amino acids of the extracellular region and / or transmembrane region of human FCGR3A. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises a portion of the human FCGR3A gene. In some embodiments, the portion of the human FCGR3A gene can be a genomic DNA sequence, a CDS or a CDNA sequence. In some embodiments, the portion of the human FCGR3A gene comprises all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or a portion of exon 6 of the human FCGR3A gene. Preferably, the portion of exon 6 of the human FCGR3A gene comprises at least 5bp of continuous nucleotide sequence at the 5' end and / or at least 5bp of continuous nucleotide sequence at the 3' end of exon 6. In some embodiments, the sequence encoding human or humanized FCGR3A further comprises the 5'UTR and / or 3'UTR of human FCGR3A. In some embodiments, the portion of the human FCGR3A gene also comprises at least 50bp of continuous nucleotide sequence upstream of the 5'UTR of the human FCGR3A gene and / or at least 50bp of continuous nucleotide sequence downstream of the 3'UTR. In some embodiments, the nucleotide sequence encoding human or humanized FCGR3A comprises at least 4262bp upstream of the human 5'UTR. Preferably, the nucleotide sequence also comprises at least 5724bp of continuous nucleotides downstream of the human 3'UTR.In some embodiments, the portion of the human FCGR3A gene comprises at least 50 bp of continuous nucleotide sequence upstream of the 5'UTR of the human FCGR3A gene to at least 5 bp of continuous nucleotide sequence at the 5' end of exon 6, and at least 5 bp of continuous nucleotide sequence at the 3' end of exon 6 to at least 50 bp of continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene. In some embodiments, the portion of the human FCGR3A gene comprises intron 1, intron 2 and / or intron 3 of the human FCGR3A gene. In some embodiments, the nucleotide sequence of the portion of the human FCGR3A gene comprises or does not comprise a mutation, such as a mutation of T at position 661 to G, resulting in a mutation of F to V in the amino acid sequence of the encoded protein. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises a nucleotide sequence encoding the extracellular region and / or transmembrane region of human FCGR3A. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises a nucleotide sequence encoding the cytoplasmic region of non-human animal FCGR4. In some embodiments, the nucleotide sequence of the humanized FCGR3A further comprises a portion of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the portion of the endogenous FCGR4 gene of a non-human animal may be a genomic DNA sequence, a CDS or a cDNA sequence. In some embodiments, the portion of the endogenous FCGR4 gene of a non-human animal comprises a portion of exon 5 of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the portion of exon 5 of the endogenous FCGR4 gene of a non-human animal comprises at least 5 bp of continuous nucleotide sequence. In some embodiments, the portion of exon 5 of the endogenous FCGR4 gene of a non-human animal comprises at least a nucleotide sequence encoding a cytoplasmic region of a non-human animal. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises from 5'-3': A) a first sequence: a nucleotide sequence encoding all or part of the extracellular region and transmembrane region of human FCGR3A (preferably also comprising a nucleotide sequence encoding a signal peptide); and B) a second sequence: a nucleotide sequence encoding all or part of the cytoplasmic region of the endogenous FCGR4 of a non-human animal. In some embodiments, the amino acid sequence encoded by the first sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence at positions 1-229 of SEQ ID NO: 2 or SEQ ID NO: 35, and the amino acid sequence encoded by the second sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence at positions 225-249 of SEQ ID NO: 1.In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises SEQ ID NO: 5 or SEQ ID NO: 5 at position 6786 where G is mutated to T, or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the nucleotide sequence shown in SEQ ID NO: 5 or SEQ ID NO. 5 at position 6786 where G is mutated to T. In some embodiments, the mRNA transcribed from the modified FCGR3A gene in the genome of the non-human animal comprises SEQ ID NO: 6 or SEQ ID NO: 34, or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the nucleotide sequence shown in SEQ ID NO: 6 or SEQ ID NO: 34. In some embodiments, the expression of the nucleotide sequence of human or humanized FCGR3A is regulated by a regulatory element, and the regulatory element is preferably a regulatory element of human FCGR3A and / or a regulatory element of non-human animal FCGR4 (e.g., promoter, 5'UTR and / or 3'UTR). In some embodiments, the endogenous FCGR4 protein of the non-human animal is not expressed or the expression level is reduced compared to FCGR4 in wild-type animals. In some embodiments, the modified FCGR3A gene in the genome of the non-human animal is homozygous or heterozygous for the endogenous replaced locus.
[0008] In one aspect, the present invention provides a non-human animal or a method for constructing the same, wherein the non-human animal comprises at least one cell comprising a nucleotide sequence encoding a human or humanized FCGR3A protein, wherein the humanized FCGR3A protein comprises at least 50, 100, 200, 210, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 240, 250, 251, 252, 253 or 254 consecutive amino acids identical to the sequence of human FCGR3A protein. In some embodiments, the humanized FCGR3A protein comprises at least 50, 100, 200, 210, 220, 221, 222, 223, 224, 225, 226, 227, 228 or 229 consecutive amino acids identical to the sequence of human FCGR3A signal peptide, extracellular region and transmembrane region. In some embodiments, the humanized FCGR3A protein is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence of positions 1-229 of SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 35. In some embodiments, the humanized FCGR3A protein comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 21, 22, 23, 24 or 25 consecutive amino acids that are identical to the consecutive amino acid sequence of the endogenous cytoplasmic region of a non-human animal. In some embodiments, the humanized FCGR3A protein is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence of positions 225-249 of SEQ ID NO: 1. In some embodiments, the nucleotide sequence of human or humanized FCGR3A is operably linked to a human or endogenous regulatory element. In some embodiments, the nucleotide sequence of the human or humanized FCGR3A can be integrated into the endogenous FCGR4 locus of the non-human animal. In some embodiments, the human or humanized FCGR3A protein has at least one activity, such as non-human animal FCGR4 activity and / or human FCGR3A activity.
[0009] In one aspect, the present invention provides a method for constructing a genetically modified non-human animal, wherein in at least one cell of the non-human animal, at the non-human animal endogenous FCGR4 locus, a nucleotide sequence comprising human or humanized FCGR3A is used to replace the non-human animal endogenous FCGR4 gene. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises a portion of the human FCGR3A gene. In some embodiments, the portion of the human FCGR3A gene comprises all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or a portion of exon 6 of the human FCGR3A gene. Preferably, the portion of exon 6 of the human FCGR3A gene comprises at least 5-1441bp of exon 6, for example 5, 10, 50, 100, 110, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1253, 1300, 1350, 1360, 1361, 1362, 1363, 1364, 1365, 1400, 1440 or 1441bp of consecutive nucleotides. Further preferably, the portion of exon 6 of the human FCGR3A gene comprises at least 5-110bp, for example 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 105 or 110bp of continuous nucleotide sequence from the 5' end of exon 6, and / or, comprises at least 5-1253bp, for example 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200 or 1253bp of continuous nucleotide sequence from the 3' end of exon 6. In some embodiments, the portion of the human FCGR3A gene comprises at least 50-10000 bp upstream of the 5'UTR of the human FCGR3A gene, such as 50, 100, 500, 1000, 2000, 3000, 4000, 4262, 5000, 6000, 7000, 8000, 9000 or 10000 bp of continuous nucleotide sequence (preferably comprising at least 4000-5000 bp upstream of the 5'UTR of the human FCGR3A gene). bp continuous nucleotide sequence), and / or, at least 50-10000bp, such as 50, 100, 500, 1000, 2000, 3000, 4000, 5000, 5724, 6000, 7000, 8000, 9000 or 10000bp continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene (preferably comprising at least 5000-6000bp continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene). In some embodiments, the portion of the human FCGR3A gene comprises intron 1, intron 2 and / or intron 3 of the human FCGR3A gene.In some embodiments, the nucleotide sequence of the humanized FCGR3A further comprises a portion of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the portion of the endogenous FCGR4 gene of a non-human animal comprises a portion of exon 5 of the endogenous FCGR4 gene of a non-human animal; preferably, the portion of exon 5 of the endogenous FCGR4 gene of a non-human animal comprises at least 5-625 bp, such as 5, 10, 50, 70, 75, 76, 77, 78, 79, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620 or 625 bp of continuous nucleotide sequence, preferably, the portion of exon 5 of the endogenous FCGR4 gene of a non-human animal comprises a nucleotide sequence encoding the cytoplasmic region of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the amino acid sequence encoded by the nucleotide sequence of the humanized FCGR3A comprises SEQ ID NO: 7 or SEQ ID NO: 33, or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the amino acid sequence shown in SEQ ID NO: 7 or SEQ ID NO: 33. In some embodiments, all or part of exons 1-5 of the endogenous FCGR4 gene of the non-human animal are replaced. In some embodiments, the replaced endogenous FCGR4 gene of the non-human animal also comprises at least 50-10000bp, for example 50, 100, 500, 1000, 2000, 3000, 4000, 5000, 6000, 6500, 6700, 6764, 7000, 8000, 9000 or 10000bp of consecutive nucleotides upstream of the 5'UTR of the endogenous FCGR4 gene of the non-human animal, and / or, comprises at least 50-1000bp, for example 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 800, 872, 900, 950 or 1000bp of consecutive nucleotides downstream of the 3'UTR of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the endogenous FCGR4 protein of the non-human animal is not expressed or the expression level is reduced compared to FCGR4 in wild-type animals. In some embodiments, the nucleotide sequence of the human or humanized FCGR3A is operably linked to human or non-human animal endogenous regulatory elements, such as promoters, 5'UTR and / or 3'UTR. In some embodiments, the non-human animal is a mammal, such as a monkey or a rodent. In some embodiments, the rodent includes a mouse or a rat.In some embodiments, the non-human animal also includes nucleotide sequences of human or humanized proteins encoded by other genes, and the human or humanized proteins include at least one of NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA4.
[0010] In one aspect, the present invention provides a method for constructing a genetically modified non-human animal cell expressing human or humanized FCGR3A, the construction method comprising replacing a nucleotide sequence encoding an endogenous FCGR4 region of a non-human animal with a nucleotide sequence of a human or chimeric FCGR3A (e.g., a nucleotide sequence of a humanized FCGR3A) at an endogenous FCGR4 locus of a non-human animal, producing a genetically modified non-human animal cell, the genetically modified non-human animal cell expressing a human or humanized FCGR3A protein. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or a portion of exon 6 of a human FCGR3A gene, and a portion of exon 5 of an endogenous FCGR4 gene of a non-human animal. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises intron 1, intron 2 and / or intron 3 of a human FCGR3A gene. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises or does not comprise intron 4 and intron 5. In some embodiments, the nucleotide sequence of the humanized FCGR3A comprises at least 50 bp of continuous nucleotides upstream of the 5'UTR of the human FCGR3A gene, and / or at least 50 bp of continuous nucleotides downstream of the 3'UTR. In some embodiments, the amino acid sequence encoded by the nucleotide sequence of the humanized FCGR3A is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence shown in SEQ ID NO: 7 or SEQ ID NO: 33. In some embodiments, the nucleotide sequence of the humanized FCGR3A is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 5 or SEQ m NO: 5, wherein position 6786 is mutated from G to T. In some embodiments, the nucleotide sequence encoding the endogenous FCGR4 region of the non-human animal that is replaced comprises all of exons 1-5 of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the replaced non-human animal endogenous FCGR4 gene further comprises at least 50 bp of continuous nucleotides upstream of the non-human animal endogenous 5'UTR, and / or at least 50 bp of continuous nucleotides downstream of the non-human animal endogenous 3'UTR. In some embodiments, the nucleotide sequence of the human or humanized FCGR3A is operably linked to a regulatory element endogenous to a human or non-human animal, such as a promoter, a 5'UTR and / or a 3'UTR. In some embodiments, the non-human animal is a mouse.
[0011] In one aspect, the present invention provides a method for determining the effectiveness of a therapeutic agent in treating a disease, the method comprising: 1) administering a therapeutic agent to the above-mentioned non-human animal or the non-human animal obtained by the above-mentioned construction method, wherein the non-human animal suffers from a disease; 2) determining the inhibitory effect of the therapeutic agent on the disease. In some embodiments, the therapeutic agent comprises one or more of an anti-FCGR3A antibody, an oligonucleotide drug, or a polypeptide drug. In some embodiments, the therapeutic agent further comprises an additional therapeutic agent, such as one or more of an anti-PD-1 antibody, an anti-PD-L1 antibody, or an anti-CTLA4 antibody. In some embodiments, the disease comprises a tumor, an inflammation, or an immune disease. In some embodiments, the tumor comprises one or more of a solid tumor, a digestive tract cancer, a melanoma, a gastric cancer, an endometrial cancer, a colon cancer, a lymphoma, a breast cancer, an endocrine cancer, a lung cancer, a kidney cancer, multiple myeloma, a non-Hodgkin's lymphoma, a pancreatic cancer, or an ovarian cancer. In some embodiments, the immune disease includes one or more of AIDS, osteoporosis, myasthenia gravis, graft-versus-host disease (GVHD), psoriasis, allergy, asthma, atopic dermatitis, myocarditis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune liver disease, pain or nervous system disease. In some embodiments, the inflammation includes one or more of degenerative inflammation, exudative inflammation (e.g., serous inflammation, fibrin inflammation, suppurative inflammation, hemorrhagic inflammation, necrotic inflammation, catarrhal inflammation), proliferative inflammation, specific inflammation (e.g., tuberculosis, syphilis, leprosy or lymphogranuloma) or inflammatory bowel disease. In some embodiments, the tumor comprises one or more tumor cells injected into a non-human animal. In some embodiments, the inhibitory effect of the therapeutic agent on the tumor is determined by measuring the tumor volume of the non-human animal.
[0012] In one aspect, the present invention provides a method for determining the toxicity of an FCGR3A therapeutic agent, the method comprising: 1) administering an FCGR3A therapeutic agent to the above-mentioned non-human animal or a non-human animal obtained by the above-mentioned construction method; 2) determining the effect of the FCGR3A therapeutic agent on the non-human animal. In some embodiments, the determination of the effect of the FCGR3A therapeutic agent on the non-human animal comprises measuring the weight of the non-human animal or a blood test. In some embodiments, the blood test comprises one or more of red blood cell count, hematocrit, or hemoglobin content.
[0013] In one aspect, the present invention provides a humanized FCGR3A protein, the humanized FCGR3A protein comprising a portion of a human FCGR3A protein and a portion of an endogenous FCGR4 protein of a non-human animal. In some embodiments, the humanized FCGR3A protein comprises a transmembrane region of a human FCGR3A protein, an extracellular region of a human FCGR3A protein, and a cytoplasmic region of an endogenous FCGR4 protein of a non-human animal. In some embodiments, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO.2 or SEQ ID NO: 2, positions 1-229, or SEQ ID NO: 35 or SEQ ID NO: 35, positions 1-229; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity with SEQ ID NO: 2 or SEQ ID NO: 2, positions 1-229, or SEQ ID NO. 35 or SEQ ID NO: 35, positions 1-229. In some embodiments, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249, or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249. In some embodiments, the humanized FCGR3A protein comprises SEQ ID NO: 7 or SEQ ID NO: 33, or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO. 33.
[0014] In one aspect, the present invention provides a humanized FCGR3A gene, which encodes the above-mentioned humanized FCGR3A protein. In some embodiments, the humanized FCGR3A gene comprises all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or part of exon 6 of the human FCGR3A gene. Preferably, the humanized FCGR3A gene comprises intron 1, intron 2 and / or intron 3 of the human FCGR3A gene. The humanized FCGR3A gene also comprises part of exon 5 of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the humanized FCGR3A gene comprises a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 27, 28, 29, 30 or 34, or comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 27, 28, 29, 30 or 34.
[0015] In one aspect, the present invention provides a cell, tissue or organ, wherein the cell, tissue or organ expresses the humanized FCGR3A protein and / or the cell, tissue or organ comprises the humanized FCGR3A gene.
[0016] In one aspect, the present invention provides an animal model, wherein the animal model expresses the humanized FCGR3A protein and / or the animal model comprises the humanized FCGR3A gene.
[0017] In one aspect, the present invention provides an application of the non-human animal, the non-human animal obtained by the construction method, the humanized FCGR3A protein, the humanized FCGR3A gene, the cell, tissue or organ or the animal model. In some embodiments, the application includes: A) application in the development of products involving immune processes related to FCGR3A in human cells; B) application as a model system related to FCGR3A in pharmacology, immunology, microbiology and medical research; C) application involving the production and use of animal experimental disease models for FCGR3A-related etiology research and / or for the development of diagnostic strategies and / or for the development of treatment strategies; D) application in the screening, efficacy detection, efficacy evaluation, verification or evaluation of human FCGR3A signaling pathway regulators in vivo; or, E) application in the study of FCGR3A gene function, the study of drugs and efficacy targeting human FCGR3A target sites, and the study of drugs for the treatment of diseases related to FCGR3A.
[0018] Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as those commonly understood by those of ordinary skill in the art to which the invention belongs. This application describes methods and materials for use in the present invention; other suitable methods and materials known in the art may be used. The materials, methods, and examples are exemplary and non-limiting only. All publications, patent applications, patents, sequences, database entries, and other references mentioned in this application are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.
[0019] The term "all or part" in the present invention, "all" refers to the whole, and "part" refers to a part of the whole, or an individual part that constitutes the whole.
[0020] The term "locus" in the present invention refers to the position of a gene on a chromosome in a broad sense, and refers to a DNA fragment on a gene in a narrow sense, which can be a gene or a part of a gene. For example, the "endogenous FCGR4 locus of a non-human animal" can be any DNA fragment of the FCGR4 gene.
[0021] The term "portion of exon XX" of the present invention means a continuous or intermittent nucleotide sequence of several, dozens, hundreds or thousands that is consistent with the entire exon nucleotide sequence, for example a portion of exon 6 of human FCGR3A gene, including continuous or intermittent 5-1441bp, for example 5, 10, 50, 100, 110, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1253, 1300, 1350, 1360, 1361, 1362, 1363, 1364, 1365, 1400, 1440 or 1441bp of continuous nucleotides. In some embodiments, the portion of exon 6 of the human FCGR3A gene includes several intervals of nucleotide sequences, for example, the portion of exon 6 of the human FCGR3A gene includes at least 5-110bp, for example, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 105 or 110bp of continuous nucleotide sequence at the 5' end of exon 6, and / or, includes at least 5-1253bp, for example, 5, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200 or 1253bp of continuous nucleotide sequence at the 3' end of exon 6.
[0022] The term "exon XX-XXX" or "exon XX to XXX" or "exon XX to exon XXX" of the present invention refers to the entire nucleotide sequence from one exon to another exon and the introns in between, for example, the entire nucleotide sequence of exons 1-5 includes exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4 and exon 5.
[0023] The term "intron xx" in the present invention refers to an intron between two exons, for example, intron 1 refers to an intron between exon 1 and exon 2.
[0024] The term "comprising" or "including" in the present invention is an open-ended writing method, which contains the specified components or steps described, as well as other specified components or steps that will not be substantially affected. When used to describe a protein or nucleotide sequence, the protein or nucleotide may be composed of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleotide, but still have the same or similar activity as the original sequence.
[0025] The term "and / or" of the present invention includes all combinations of items connected by the term, and each combination should be deemed to have been listed separately in the present application. For example, "A and / or B" includes "A", "B" and "A and B", and "A, B and / or C" includes "A", "B", "C", "A and B", "A and C", "B and C" and "A and B and C".
[0026] The present invention term " stringent conditions " refers to the condition that forms specific hybridization and does not form non-specific hybridization, comprises high, medium or low stringency conditions, described stringent conditions are well known to those skilled in the art, for example can refer to Molecular Cloning (Third Edition, Cold Spring Harbor Laboratory Press, New York), Current protocols in molecular biology (edited by Frederick M.Ausubel et al., 1987) and SHORT PROTOCOLS IN MOLECULAR BIOLOGY, edAusubel, et al. are incorporated to the application by reference, stringent conditions depend on sequence. Longer sequence specific hybridization at higher temperature.
[0027] Those skilled in the art can easily discern other aspects and advantages of the present application from the following detailed description.
[0028] Detailed description
[0029] FCGR3A
[0030] In the human genome, the FCGR3A gene (NCBI Gene ID: 2214) contains 6 exons, namely exon 1, exon 2, exon 3, exon 4, exon 5 and exon 6 ( Figure 1 ). The nucleotide sequence of human FCGR3A mRNA is NM_001127595.2, and the amino acid sequence of human FCGR3A is NP_001121067.1 (SEQ ID NO: 2). The corresponding position of each exon in the nucleotide sequence and amino acid sequence of the transcript NM_001127595.2 and its encoded protein NP_001121067.1 is shown in Table 1:
[0031] Table 1
[0032]
[0033] In the mouse genome, the FCGR4 gene (NCBI Gene ID: 246256) contains five exons, namely exon 1, exon 2, exon 3, exon 4 and exon 5 ( Figure 1 ). The nucleotide sequence of mouse FCGR4 mRNA is NM_144559.2, and the amino acid sequence of mouse FCGR4 is NP_653142.2 (SEQ ID NO: 1). The corresponding position of each exon in the nucleotide sequence and amino acid sequence of the transcript NM_144559.2 and its encoded protein NP_653142.2 is shown in Table 2:
[0034] Table 2
[0035]
[0036]
[0037] FCGR3A genes, proteins and gene loci of other species are also known in the art. For example, Rattus norvegicus (rat), Macaca mulatta (rhesus monkey), Canis lupus familiaris (dog), Sus scrofa (pig). The relevant information of these genes (such as intron sequence, exon sequence and amino acid sequence) can be found in NCBI, the entire contents of which are incorporated into this application by reference.
[0038] The present invention provides a human or chimeric (e.g., humanized) FCGR3A nucleotide sequence or a human or chimeric (e.g., humanized) FCGR3A amino acid sequence. In some embodiments, all or part of the nucleotide sequence of exon 1, exon 2, exon 3, exon 4, and exon 5 of the endogenous FCGR4 gene of a non-human animal, and / or all or part of the nucleotide sequence encoding the signal peptide, extracellular region, transmembrane region, and / or cytoplasmic region of the endogenous FCGR4 protein of a non-human animal is replaced by the nucleotide sequence of the human or humanized FCGR3A gene. By “portion” is meant at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 650, 700, 800, 900, 1000, 1200, 1250, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10 ...50, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 1100 200, 210, 220, 221, 222, 223, 224, 225, 230, 240, 245 or 249 consecutive amino acid sequences. In some embodiments, the "portion" is consistent or identical to exon 1, exon 2, exon 3, exon 4 and / or exon 5 of the endogenous FCGR4 gene of a non-human animal, or the nucleotide sequence encoding the signal peptide, extracellular region, transmembrane region and / or cytoplasmic region of the endogenous FCGR4 protein of a non-human animal by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99.5%. In some embodiments, "partial" or "complete" sequence of exon 1, exon 2, exon 3, exon 4 and exon 5 of the endogenous FCGR4 gene of a non-human animal (e.g., the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence of the endogenous FCGR4 gene of a non-human animal) is replaced by a human or humanized FCGR3A gene sequence (e.g., the 5'UTR upstream nucleotide sequence of the human FCGR3A gene to the 5' end of exon 6, part of exon 5 of the endogenous FCGR4 gene of a non-human animal, the 3' end of exon 6 of the human FCGR3A gene to the 3'UTR downstream nucleotide sequence).
[0039] In some embodiments, the present invention provides a genetically modified non-human animal, the genome of the genetically modified non-human animal comprising a human or chimeric (e.g., humanized) FCGR3A nucleotide sequence. In some embodiments, the protein encoded by the chimeric FCGR3A nucleotide sequence comprises a human or humanized signal peptide, a human or humanized extracellular region, a human or humanized transmembrane region, and a non-human animal endogenous cytoplasmic region. In some embodiments, the protein encoded by the chimeric FCGR3A nucleotide sequence is at least 70%, 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence shown in all or part of SEQ ID NO: 1, 2 or 7. In some embodiments, the nucleotide sequence contained in the genome of the genetically modified non-human animal is at least 70%, 80%, 85%, 90%, 95% or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 10, 11, 27, 28, 29, 30 or 34.
[0040] In some embodiments, the genetically modified non-human animal comprises a sequence encoding a human or humanized FCGR3A protein. In some embodiments, the humanized FCGR3A protein comprises, from the N-terminus to the C-terminus, a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic region. In some embodiments, the humanized FCGR3A protein comprises a human or humanized signal peptide, for example, the sequence comprised by the human or humanized signal peptide is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 1-16 of SEQ ID NO: 2. In some embodiments, the humanized FCGR3A protein comprises an endogenous signal peptide of a non-human animal, for example, the sequence comprised by the endogenous signal peptide of a non-human animal is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 1-20 of SEQ ID NO: 1. In some embodiments, the humanized FCGR3A protein comprises a human or humanized extracellular region, for example, the human or humanized extracellular region comprises a sequence that is identical or at least 70%, 80%, 85%, 90%, 95% or 99.5% identical to amino acids 17-208 of SEQ ID NO: 2 or 17-208 of SEQ ID NO: 35. In some embodiments, the humanized FCGR3A protein comprises an extracellular region endogenous to a non-human animal, for example, the sequence comprised by the extracellular region endogenous to a non-human animal is identical or at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 21-203 of SEQ ID NO: 1. In some embodiments, the humanized FCGR3A protein comprises a human or humanized transmembrane region, for example, a human or humanized transmembrane region comprises a sequence that is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 209-229 of SEQ ID NO: 2. In some embodiments, the humanized FCGR3A protein comprises a transmembrane region endogenous to a non-human animal, for example, a transmembrane region endogenous to a non-human animal comprises a sequence that is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 204-224 of SEQ ID NO: 1. In some embodiments, the humanized FCGR3A protein comprises a human or humanized cytoplasmic region, for example, a human or humanized cytoplasmic region comprises a sequence that is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 230-254 of SEQ ID NO: 2. In some embodiments, the humanized FCGR3A protein comprises a non-human animal endogenous cytoplasmic region, for example, the non-human animal endogenous cytoplasmic region comprises a sequence that is at least 70%, 80%, 85%, 90%, 95% or 99% identical to amino acids 225-249 of SEQ ID NO: 1.In some embodiments, the humanized FCGR3A protein comprises the signal peptide of human FCGR3A protein, the extracellular region of human FCGR3A protein, the transmembrane region of human FCGR3A protein, and the cytoplasmic region of endogenous FCGR4 protein of a non-human animal, for example, the humanized FCGR3A protein comprises the amino acid sequence of positions 1-229 of SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 35, and positions 225-249 of SEQ ID NO: 1.
[0041] In some embodiments, the nucleotide sequence encoding the signal peptide, extracellular region, transmembrane region and cytoplasmic region of the endogenous FCGR4 protein (SEQ ID NO: 1) of a non-human animal is replaced or inactivated. In some embodiments, it is replaced by the nucleotide sequence encoding human or humanized FCGR3A (SEQ ID NO: 5 or SEQ ID NO: 5 position 6786 is mutated from G to T). In some embodiments, the nucleotide sequence encoding SEQ ID NO: 1 or SEQ ID NO: 1 amino acids 1-224 is replaced.
[0042] In some embodiments, the genetically modified non-human animal comprises a human or humanized FCGR3A gene. In some embodiments, the humanized FCGR3A gene comprises, from 5' to 3', exon 1 of the human FCGR3A gene, exon 2 of the human FCGR3A gene, exon 3 of the human FCGR3A gene, and humanized exon 4. Preferably, humanized exon 4 is a chimeric sequence of human and non-human animals, comprising part of the chimeric CDS sequence of the human FCGR3A gene and endogenous FCGR4 of non-human animals. Preferably, it comprises all of exon 4 of the human FCGR3A gene, all of exon 5 of the human FCGR3A gene, part of exon 6 of the human FCGR3A gene, and part of exon 5 of the endogenous FCGR4 gene of non-human animals. In some embodiments, the humanized FCGR3A gene further comprises a 5'UTR upstream nucleotide sequence and / or a 3'UTR downstream nucleotide sequence of the human FCGR3A gene.
[0043] In some embodiments, the genetically modified non-human animal comprises a human or humanized FCGR3A gene. In some embodiments, the humanized FCGR3A gene comprises 4 exons. In some embodiments, the humanized FCGR3A gene comprises a human or humanized 5'UTR. In some embodiments, the humanized FCGR3A gene comprises a human or humanized 3'UTR. In some embodiments, the humanized FCGR3A gene comprises a 5'UTR of an endogenous FCGR4 gene of a non-human animal. In some embodiments, the humanized FCGR3A gene comprises a 3'UTR of an endogenous FCGR4 gene of a non-human animal.
[0044] In some embodiments, the genetically modified non-human animal may express human FCGR3A and / or chimeric (e.g., humanized) FCGR3A protein. Further, the amino acid sequence of the humanized FCGR3A protein is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7 or SEQ ID NO: 33.
[0045] In some embodiments, the genetically modified non-human animal expresses human FCGR3A and / or chimeric FCGR3A protein (e.g., humanized FCGR3A) under human and / or endogenous regulatory elements (such as promoters, 5'UTRs and / or 3'UTRs). Replacement of the endogenous FCGR4 locus of the non-human animal provides a non-human animal that expresses human or chimeric FCGR3A protein (e.g., humanized FCGR3A) in the same type of cells. The genetically modified non-human animal does not show potential diseases observed in certain other transgenic non-human animals known in the art. The human FCGR3A or chimeric FCGR3A protein expressed in the non-human animal can maintain one or more functions, such as the function of the wild-type non-human animal endogenous FCGR4 protein and / or the function of the human FCGR3A protein. In some embodiments, the genetically modified non-human animal does not express the non-human animal endogenous FCGR4 protein. In some embodiments, the expression of the endogenous FCGR4 protein of the genetically modified non-human animal is reduced. The "endogenous FCGR4 protein" refers to the FCGR4 protein encoded by the endogenous FCGR4 nucleotide sequence of a non-human animal (eg, mouse) before genetic modification.
[0046] In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence encoding an amino acid that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence of human FCGR3A protein (SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229) and / or endogenous FCGR4 protein of non-human animal (SEQ ID NO: 1 or SEQ ID NO: 1 positions 225-249). In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 5 position 6786 mutated from G to T.
[0047] In some embodiments, one or more cells of the genetically modified non-human animal express a human or chimeric FCGR3A protein (e.g., a humanized FCGR3A protein). In some embodiments, the human or humanized FCGR3A protein comprises at least 50, 100, 200, 210, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 240, 250, 251, 252, 253, or 254 consecutive amino acids identical to the amino acid sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 2, positions 1-229, or SEQ ID NO: 35 or SEQ ID NO: 35, positions 1-229. In some embodiments, the humanized FCGR3A protein comprises at least 20, 25, 50, 100, 200, 210, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 240 or 249 consecutive amino acids identical to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249.
[0048] In some embodiments, the genome of the genetically modified non-human animal comprises a humanized FCGR3A gene that is heterozygous or homozygous for the endogenous modified locus.
[0049] In some embodiments, the humanized FCGR3A genome comprises the 5'UTR of the human FCGR3A gene. In some embodiments, the humanized FCGR3A genome comprises an endogenous (e.g., mouse) 5'UTR. In some embodiments, the humanized FCGR3A genome comprises the 3'UTR of the human FCGR3A gene. In some embodiments, the humanized FCGR3A genome comprises an endogenous (e.g., mouse) 3'UTR. Where appropriate, based on the similarity of human and non-human animal sequences, it can be reasonably inferred that the genes of non-human animals and humans are similarly regulated. As described in the present invention, the humanized FCGR3A in the genome of a genetically modified non-human animal comprises a replacement of the endogenous FCGR4 locus of the non-human animal, which retains human regulatory elements and comprises a humanized FCGR3A coding sequence. The expression of humanized FCGR3A in a genetically modified heterozygous non-human animal or homozygous non-human animal is completely normal.
[0050] In some embodiments, the present invention provides a genetically modified non-human animal, the genome of the genetically modified non-human animal comprising a deletion of an endogenous FCGR4 gene of the non-human animal, wherein the deletion of the endogenous FCGR4 gene of the non-human animal comprises exon 1, exon 2, exon 3, exon 4 and / or exon 5, or a portion of the endogenous FCGR4 locus.
[0051] In some embodiments, the deletion of the endogenous FCGR4 gene of the non-human animal further comprises one or more introns or portions of introns, wherein the introns are selected from intron 1, intron 2, intron 3 and / or intron 4 of the endogenous FCGR4 gene of the non-human animal.
[0052] In some embodiments, the present invention provides a humanized FCGR3A genomic DNA sequence, a construct expressing the amino acid sequence of a humanized FCGR3A protein; or a cell comprising the construct; or a tissue or organ comprising the cell.
[0053] In some embodiments, the present invention provides a chimeric (eg, humanized) FCGR3A nucleotide sequence and / or amino acid sequence. In some embodiments, the chimeric FCGR3A nucleotide sequence and / or amino acid sequence is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% identical to an endogenous FCGR4 mRNA of a non-human animal (e.g., NM_144559.2), an endogenous FCGR4 amino acid sequence of a non-human animal (e.g., NP_653142.2, SEQ ID NO: 1), or a portion thereof (e.g., a portion of exon 5). In some embodiments, the chimeric FCGR3A nucleotide sequence and / or amino acid sequence is identical to a human FCGR3A mRNA sequence (e.g., NM_001127595.2), a human FCGR3A amino acid sequence (e.g., NP_001121067.1, SEQ ID NO: 2), or a portion thereof (e.g., the nucleotide sequence upstream of the 5'UTR to the 5' end of exon 6, the 3' end of exon 6 to the nucleotide sequence downstream of the 3'UTR) having a sequence identity or identity of at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%.
[0054] In some embodiments, the nucleotide sequence encoding amino acids 1-249 of a non-human animal FCGR4 (e.g., mouse FCGR4, SEQ ID NO: 1) is replaced by a nucleotide sequence encoding amino acids 1-249 of human FCGR3A (SEQ ID NO: 2, positions 1-229 or SEQ ID NO: 35, positions 1-229) and a chimeric sequence encoding amino acids of non-human animal FCGR4 (SEQ ID NO: 1, positions 225-249).
[0055] In some embodiments, any of the above-described nucleotide sequences is operably linked to a regulatory element, such as a human FCGR3A promoter, a non-human animal endogenous FCGR4 promoter, an inducible promoter or an enhancer.
[0056] In some embodiments, at least a portion of the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, for example, a continuous or non-contiguous nucleotide sequence) is different from all or part of the endogenous FCGR4 nucleotide sequence of the non-human animal (e.g., all of exon 1 to part of exon 5 of the mouse FCGR4 gene transcript NM_144559.2).
[0057] In some embodiments, at least a portion of the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., a continuous or non-contiguous nucleotide sequence) is identical to all or part of an endogenous FCGR4 nucleotide sequence of a non-human animal (e.g., a portion of exon 5 of the mouse FCGR4 gene transcript NM_144559.2).
[0058] In some embodiments, at least a portion of the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, e.g., a continuous or non-contiguous nucleotide sequence) is different from all or a portion of the human FCGR3A nucleotide sequence (e.g., a portion of exon 6 of the human FCGR3A gene transcript NM_001127595.2).
[0059] In some embodiments, at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides, for example, a continuous or non-contiguous nucleotide sequence) of the chimeric nucleotide sequence is identical to all or part of the human FCGR3A nucleotide sequence (e.g., the nucleotide sequence from the 5'UTR upstream to the 5' end of exon 6 of the human FCGR3A gene transcript NM_001127595.2, and the nucleotide sequence from the 3' end of exon 6 to the 3'UTR downstream).
[0060] In some embodiments, at least a portion of the amino acid sequence encoded by the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, such as continuous or non-contiguous amino acid residues) is different from all or part of the amino acid sequence of endogenous FCGR4 protein of non-human animals (e.g., amino acids 1-224 of endogenous FCGR4 protein sequence NP_653142.2 (SEQ ID NO: 1) of non-human animals).
[0061] In some embodiments, at least a portion of the amino acid sequence encoded by the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, for example, consecutive or non-consecutive amino acid residues) is identical to all or part of the amino acid sequence of endogenous FCGR4 protein of non-human animals (e.g., amino acids 225-249 of endogenous FCGR4 protein sequence NP_653142.2 (SEQ ID NO: 1) of non-human animals).
[0062] In some embodiments, at least a portion of the amino acid sequence encoded by the chimeric nucleotide sequence (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, for example, consecutive or non-consecutive amino acid residues) is different from all or part of the amino acid sequence of human FCGR3A protein (e.g., amino acids 230-254 of human FCGR3A protein sequence NP_001121067.1 (SEQ ID NO: 2)).
[0063] In some embodiments, at least a portion (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acid residues, for example, consecutive or non-consecutive amino acid residues) of the amino acid sequence encoded by the chimeric nucleotide sequence is identical to all or part of the amino acid sequence of the human FCGR3A protein (e.g., amino acids 1-229 of the human FCGR3A protein sequence NP_001121067.1 (SEQ ID NO: 2) or amino acids 1-229 of SEQ ID NO: 35).
[0064] The present invention also provides a humanized FCGR3A amino acid sequence, wherein the humanized FCGR3A amino acid sequence comprises any one of the following groups:
[0065] A) the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 1 positions 225 to 249 or SEQ ID NO: 2 or SEQ ID NO: 2 positions 1 to 229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1 to 229 or SEQ ID NO: 7 or SEQ ID NO: 33;
[0066] B) is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identical to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:1 positions 225-249 or SEQ ID NO:2 or SEQ ID NO:2 positions 1-229 or SEQ ID NO:35 or SEQ ID NO:35 positions 1-229 or SEQ ID NO:7 or SEQ ID NO:33;
[0067] C) an amino acid sequence encoded by a nucleotide sequence, wherein the nucleotide sequence is capable of hybridizing under low stringency conditions or stringent conditions to a nucleotide sequence encoding the amino acids set forth in SEQ ID NO: 1 or SEQ ID NO: 1 positions 225 to 249 or SEQ ID NO: 2 or SEQ ID NO: 2 positions 1 to 229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1 to 229 or SEQ ID NO: 7 or SEQ ID NO: 33;
[0068] D) differs from the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:1 positions 225-249 or SEQ ID NO:2 or SEQ ID NO:2 positions 1-229 or SEQ ID NO:35 or SEQ ID NO:35 positions 1-229 or SEQ ID NO:7 or SEQ ID NO:33 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or
[0069] E) an amino acid sequence comprising a substitution, deletion and / or insertion of one or more amino acid residues compared to that shown in SEQ ID NO: 1 or SEQ ID NO: 1 positions 225-249 or SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229 or SEQ ID NO: 7 or SEQ ID NO: 33.
[0070] The present invention also provides a humanized FCGR3A nucleotide (eg, DNA or RNA) sequence, wherein the humanized FCGR3A nucleotide sequence comprises any one of the following groups:
[0071] A) a nucleic acid sequence as shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 10, 11, 27, 28, 29, 30 or 34, or a nucleic acid sequence encoding a humanized FCGR3A homologous amino acid sequence;
[0072] B) a nucleic acid sequence that can hybridize to the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 10, 11, 27, 28, 29, 30 or 34 under low stringency conditions or stringent conditions;
[0073] C) a nucleic acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.9% identical to the nucleotide sequence of SEQ ID NO: 3, 4, 5, 6, 8, 9, 10, 11, 27, 28, 29, 30, or 34;
[0074] D) the amino acid sequence encoded by it is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:1 or SEQ ID NO:1 positions 225 to 249 or SEQ ID NO:2 or SEQ ID NO:2 positions 1 to 229 or SEQ ID NO:35 or SEQ ID NO.35 positions 1 to 229 or SEQ ID NO:7 or SEQ ID NO:33;
[0075] E) the amino acid sequence encoded by the amino acid sequence differs by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid from the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 1 positions 225 to 249 or SEQ ID NO: 2 or SEQ ID NO: 2 positions 1 to 229 or SEQ ID NO: 35 or SEQ ID NO. 35 positions 1 to 229 or SEQ ID NO: 7 or SEQ ID NO: 33; or
[0076] F) The amino acid sequence encoded by the amino acid sequence is the same as that shown in SEQ ID NO: 1 or SEQ ID NO: 1 positions 225-249 or SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO. 35 positions 1-229 or SEQ ID NO: 7 or SEQ ID NO: 33, including the amino acid sequence with one or more amino acid residues replaced, deleted and / or inserted.
[0077] The present invention further provides a humanized FCGR3A genomic DNA sequence, which is obtained by reverse transcription of the mRNA transcribed from the FCGR3A genomic DNA sequence and is consistent with or complementary to a DNA sequence homologous to SEQ ID NO: 5 or SEQ ID NO: 5 at position 6786 where G is mutated to T or SEQ ID NO: 6 or SEQ ID NO: 34.
[0078] In order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are compared for the purpose of optimal comparison (e.g., for optimal comparison, gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences, and non-homologous sequences can be ignored for the purpose of comparison). The amino acid residues or nucleotides on the corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, which needs to be introduced to achieve the optimal comparison of the two sequences, taking into account the number of gaps and the length of each gap. For example, the comparison of the sequences and the determination of the percent identity between the two sequences can be completed using the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
[0079] The percentage (homology percentage) of conservative residues with similar physicochemical properties, such as leucine and isoleucine, can also be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (e.g., threonine, valine and isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage.
[0080] The present invention also provides cells, tissues and non-human animals (e.g., mice) comprising the nucleotide sequences described herein, as well as cells, tissues and non-human animals (e.g., mice) expressing human or chimeric (e.g., humanized) FCGR3A at the endogenous FCGR4 locus of non-human animals.
[0081] Genetically modified non-human animals
[0082] The "genetically modified non-human animal" of the present invention refers to a non-human animal in which at least one chromosome in the genome of the non-human animal has exogenous DNA. In some embodiments, at least one or more cells, for example, at least 1%, 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40% or 50% of the cells in the genetically modified non-human animal have exogenous DNA. The cells with exogenous DNA can be various cells, for example, somatic cells, immune cells (such as T cells, B cells, NK cells, antigen presenting cells, macrophages, dendritic cells), germ cells, blastocysts or tumor cells. In some embodiments, a genetically modified non-human animal is provided, comprising a modified endogenous FCGR4 locus, comprising an exogenous sequence (such as a human sequence), for example, replacing one or more non-human sequences with one or more human sequences or human / non-human chimeric sequences, or inserting one or more human sequences or human / non-human chimeric sequences. Non-human animals are generally able to pass genetic modifications to offspring through germline transmission.
[0083] The "chimeric (x) gene" or "chimeric (x) nucleic acid" of the present invention refers to a gene or nucleic acid, wherein two or more parts of the gene or nucleic acid are from different species, or the nucleotide sequence of at least a part of the gene or nucleic acid is different from the nucleotides in the wild-type animal. In some embodiments, at least a part of the nucleotide sequence of the chimeric (x) gene or chimeric (x) nucleic acid has two or more different species sources, for example, sequences encoding different proteins or sequences encoding the same (or homologous) proteins of two or more different species. In some embodiments, the chimeric (x) gene or chimeric (x) nucleic acid refers to a humanized (x) gene or a humanized (x) nucleic acid.
[0084] The "chimeric (x) protein" or "chimeric (x) polypeptide" of the present invention refers to a protein or polypeptide, wherein two or more parts of the polypeptide or protein are from different species, or the amino acid sequence of at least a part of the protein or polypeptide is different from the amino acid sequence in a wild-type animal. In some embodiments, at least a part of the amino acid sequence of the chimeric (x) protein or chimeric (x) polypeptide has two or more different species sources, for example, the same (or homologous) proteins of different species. In some embodiments, the chimeric (x) protein or chimeric (x) polypeptide refers to a humanized (x) protein or humanized (x) polypeptide.
[0085] The "humanized (x) protein" or "humanized (x) polypeptide" of the present invention refers to a protein or polypeptide, wherein at least a portion of the protein or polypeptide is derived from a human (x) protein or a human (x) polypeptide. In some embodiments, at least a portion of the protein or polypeptide is derived from a non-human animal. In some embodiments, the humanized (x) protein or humanized (x) polypeptide refers to a human (x) protein or a human (x) polypeptide. In some embodiments, the humanized (x) protein or humanized (x) polypeptide refers to a human / non-human animal chimeric (x) protein or a human / non-human animal chimeric (x) polypeptide.
[0086] The "humanized (x) nucleic acid" or "humanized (x) gene" of the present invention refers to a nucleic acid, wherein at least a portion of the nucleic acid is derived from a human. In some embodiments, at least a portion of the nucleic acid is derived from a non-human animal. In some embodiments, the humanized (x) nucleic acid or humanized (x) gene refers to a humanized exon, which can be a human exon or a chimeric exon.
[0087] In some embodiments, the chimeric (x) gene or chimeric (x) nucleic acid is a humanized FCGR3A gene or a humanized FCGR3A nucleic acid. In some embodiments, at least a portion of the humanized FCGR3A gene or the humanized FCGR3A nucleic acid is derived from a human FCGR3A gene. In some embodiments, at least a portion of the humanized FCGR3A gene or the humanized FCGR3A nucleic acid is derived from a non-human animal endogenous FCGR4 gene. In some embodiments, the humanized FCGR3A gene or the humanized FCGR3A nucleic acid comprises a sequence encoding a humanized FCGR3A protein. The encoded humanized FCGR3A protein has at least one activity of a human FCGR3A protein or a non-human animal endogenous FCGR4 protein.
[0088] In some embodiments, the chimeric (x) protein or chimeric (x) polypeptide is a humanized FCGR3A protein or a humanized FCGR3A polypeptide. In some embodiments, at least one or more portions of the amino acid sequence of the humanized FCGR3A protein or the humanized FCGR3A polypeptide are from human FCGR3A protein. In some embodiments, at least one or more portions of the amino acid sequence of the humanized FCGR3A protein or the humanized FCGR3A polypeptide are from endogenous FCGR4 protein of a non-human animal. In some embodiments, the humanized FCGR3A protein or the humanized FCGR3A polypeptide is functional, or has at least one activity of a human FCGR3A protein or an endogenous FCGR4 protein of a non-human animal.
[0089] In some embodiments, the humanized FCGR3A protein comprises a polypeptide sequence that is identical to 5-254 amino acids (continuous or non-continuous) of a human FCGR3A protein. In some embodiments, the length of the polypeptide sequence is 5-229, 10-229, or 10-254, such as 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 229, 230, 240, 250, or 254 amino acids.
[0090] In some embodiments, the humanized FCGR3A gene or humanized FCGR3A nucleic acid comprises a nucleotide sequence identical to 20-2153bp, 20-18965bp or 20-14002bp (continuous or non-continuous) of the human FCGR3A gene, for example, 20, 50, 100, 500, 1000, 2000, 2153, 3000, 4000, 5000, 6000, 7000, 8000, 8979, 9000, 10000, 11000, 12000, 13000, 13240, 13241, 13500, 13924, 14000, 14002, 15000, 16000, 17000, 18000 or 18965bp.
[0091] In some embodiments, the extracellular region of the humanized FCGR3A protein is human or humanized FCGR3A. In some embodiments, the signal peptide of the humanized FCGR3A protein is human or humanized FCGR3A. In some embodiments, the cytoplasmic region of the humanized FCGR3A protein is human or humanized FCGR3A. In some embodiments, the transmembrane region of the humanized FCGR3A protein is human or humanized FCGR3A. In some embodiments, the cytoplasmic region of the humanized FCGR3A protein is endogenous FCGR4 of a non-human animal.
[0092] In some embodiments, the genetically modified non-human animal comprises a modification of an endogenous FCGR4 gene site (locus) of the non-human animal. In some embodiments, the modification comprises a nucleotide sequence encoding at least a portion of a mature FCGR3A protein (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of a mature human FCGR3A protein). Although cells (e.g., ES cells, somatic cells) that may comprise the genetic modification are provided in the present invention, in many embodiments, the genetically modified non-human animal comprises a modification of an endogenous FCGR4 gene site of the non-human animal.
[0093] In some embodiments, the genetically modified non-human animal can express human FCGR3A and / or chimeric (e.g., humanized) FCGR3A at the non-human animal endogenous FCGR4 locus, wherein the non-human animal endogenous FCGR4 gene has been replaced or inserted with a gene for human or humanized FCGR3A and / or a nucleotide sequence encoding a human or humanized FCGR3A protein or a nucleotide sequence that is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97% or 99% identical to a sequence encoding human FCGR3A. In some embodiments, the non-human animal endogenous FCGR4 locus is modified with a nucleotide sequence encoding a human or humanized FCGR3A protein.
[0094] In some embodiments, the genetically modified non-human animal can express human FCGR3A and / or chimeric FCGR3A (e.g., humanized FCGR3A) under the control of human or non-human animal endogenous regulatory elements (e.g., promoter, 5'UTR and / or 3'UTR). Insertion or replacement at the endogenous FCGR4 locus of the non-human animal provides a non-human animal that expresses human FCGR3A or chimeric FCGR3A (e.g., humanized FCGR3A) in suitable cells and is obtained in a manner that does not cause potential pathology observed in some other transgenic non-human animals known in the art. Human FCGR3A or chimeric FCGR3A (e.g., humanized FCGR3A) expressed in the non-human animal can maintain one or more functions of wild-type FCGR4 or human FCGR3A in the non-human animal. In addition, in some embodiments, the non-human animal does not express endogenous FCGR4. In some embodiments, the expression level of endogenous FCGR4 in the non-human animal is reduced compared to the expression level of FCGR4 in wild-type animals. The term "endogenous FCGR4" as used herein refers to the FCGR4 protein expressed by the endogenous FCGR4 nucleotide sequence of a non-human animal (eg, mouse) before any genetic modification.
[0095] In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence encoding at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229. In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence encoding at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to SEQ ID NO: 5 or SEQ ID NO. 5 position 6786 mutated from G to T or SEQ ID NO: 6 or SEQ ID NO: 34. In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to NM_001127595.2 at positions 1-822, or at position 661 thereof, preferably at position 661 being T or G, and at positions 901-2153. In some embodiments, the genome of the genetically modified non-human animal comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to NM_144559.2 at positions 727-804.
[0096] In some embodiments, the genome of the genetically modified non-human animal may include replacing the sequence encoding the endogenous FCGR4 region of the non-human animal with a sequence encoding human or humanized FCGR3A at the endogenous FCGR4 locus of the non-human animal. In some embodiments, the replaced sequence is any sequence of the endogenous FCGR4 locus of the non-human animal, such as exon 1, exon 2, exon 3, exon 4, exon 5, intron 1, intron 2, intron 3, intron 4, or any combination thereof. In some embodiments, the replaced sequence is within the regulatory region of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the replaced sequence is all of exons 1-5 of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the replaced sequence also comprises 6764bp upstream of the 5'UTR and 872bp downstream of the 3'UTR of the endogenous FCGR4 gene of the non-human animal.
[0097] In some embodiments, the genetically modified non-human animal may have one or more cells expressing human or chimeric FCGR3A (e.g., humanized FCGR3A), wherein the humanized FCGR3A has a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic region from the N-terminus to the C-terminus. In some embodiments, the signal peptide comprises a sequence that is at least 50%, 60%, 70%, 80%, 90%, 95%, 99% identical to the signal peptide of human FCGR3A (e.g., amino acids 1-16 of SEQ ID NO: 2). In some embodiments, the signal peptide of humanized FCGR3A has a sequence of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 16 amino acids (e.g., continuous or non-continuous) that is consistent with the signal peptide of human FCGR3A protein. In some embodiments, the extracellular region comprises a sequence that is at least 50%, 60%, 70%, 80%, 90%, 95%, 99% identical to the extracellular region of human FCGR3A (e.g., SEQ ID NO: 2, positions 17-208 or SEQ ID NO: 35, positions 17-208). In some embodiments, the extracellular region of humanized FCGR3A has a sequence of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150, 160, 170, 180, 190, 191 or 192 amino acids (continuous or non-continuous) that are identical to the extracellular region of human FCGR3A. In some embodiments, the transmembrane region comprises a sequence that is at least 50%, 60%, 70%, 80%, 90%, 95%, 99% identical to the transmembrane region of human FCGR3A (e.g., amino acids 209-229 of SEQ ID NO: 2). In some embodiments, the transmembrane region of humanized FCGR3A has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 amino acids (continuous or non-continuous) that are identical to the transmembrane region of human FCGR3A protein. In some embodiments, the cytoplasmic region comprises a sequence that is at least 50%, 60%, 70%, 80%, 90%, 95%, 99% identical to the cytoplasmic region of endogenous FCGR4 of a non-human animal (e.g., amino acids 225-249 of SEQ ID NO: 1). In some embodiments, the cytoplasmic region of humanized FCGR3A has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids (continuous or non-continuous) that are identical to the cytoplasmic region of endogenous FCGR4 of a non-human animal (e.g., mouse FCGR4).
[0098] In some embodiments, the entire signal peptide, the entire extracellular region and the entire transmembrane region of the humanized FCGR3A are derived from the human FCGR3A sequence.
[0099] In some embodiments, the genome of the genetically modified non-human animal includes: all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or part of exon 6 of the human FCGR3A gene (preferably also including intron 1, intron 2 and / or intron 3 of the human FCGR3A gene); or a nucleotide sequence encoding amino acids 1-229 of SEQ ID NO: 2 or amino acids 1-229 of SEQ ID NO: 35, preferably, also including the 5'UTR upstream nucleotide sequence and / or the 3'UTR downstream nucleotide sequence of the human FCGR3A gene. In some embodiments, the 5'UTR upstream nucleotide sequence of the human FCGR3A gene comprises at least 50-10000 bp, for example 50, 100, 500, 1000, 2000, 3000, 4000, 4262, 5000, 6000, 7000, 8000, 9000 or 10000 bp of continuous nucleotide sequence (preferably comprising at least 4000-5000 bp of continuous nucleotide sequence upstream of the 5'UTR of the human FCGR3A gene). In some embodiments, the nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene comprises at least 50-10000 bp, such as 50, 100, 500, 1000, 2000, 3000, 4000, 5000, 5724, 6000, 7000, 8000, 9000 or 10000 bp of continuous nucleotide sequence (preferably comprises at least 5000-6000 bp of continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene).
[0100] In some embodiments, the genome of the genetically modified non-human animal includes a portion of exon 5 of an endogenous FCGR4 gene of the non-human animal (e.g., mouse FCGR4). In some embodiments, the portion of exon 5 of an endogenous FCGR4 gene of the non-human animal includes at least 1, 2, 3, 4, 5, 6, 10, 20, 30, 40, 50, 60, 70, 75, 78, 80, 90, 100, 150, 200, 300, 400, 500, 600, 620, or 625 bp of nucleotides.
[0101] In some embodiments, there is a nucleotide sequence encoding a chimeric human / non-human FCGR3A polypeptide at the endogenous FCGR4 locus of a non-human animal, and the non-human animal expresses functional FCGR3A on the cell surface. In some embodiments, the human portion of the chimeric human / non-human FCGR3A polypeptide may comprise an amino acid sequence encoded by exon 1, exon 2, exon 3, exon 4, all of exon 5, and a portion of exon 6 of the human FCGR3A gene. In some embodiments, the human portion of the chimeric human / non-human FCGR3A polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95%, or 99% identical to SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229. In some embodiments, the non-human animal portion of the chimeric human / non-human FCGR3A polypeptide may comprise an amino acid sequence encoded by a portion of exon 5 of the endogenous FCGR4 gene of the non-human animal. In some embodiments, the non-human animal portion of the chimeric human / non-human FCGR3A polypeptide comprises a sequence that is at least 80%, 85%, 90%, 95% or 99% identical to SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249. In some embodiments, the modified gene in the genome of the genetically modified non-human animal is homozygous or heterozygous for the endogenous replaced locus. In some embodiments, the modified FCGR3A gene in the genome of the genetically modified non-human animal is homozygous or heterozygous for the endogenous replaced locus.
[0102] In some embodiments, the humanized FCGR3A gene comprises the 5'UTR of the human FCGR3A gene. In some embodiments, the humanized FCGR3A gene comprises the 5'UTR of the endogenous FCGR4 gene of a non-human animal (e.g., a mouse). In some embodiments, the humanized FCGR3A gene comprises the 3'UTR of the endogenous FCGR4 gene of a non-human animal (e.g., a mouse). In some embodiments, the humanized FCGR3A locus comprises the 3'UTR of the human FCGR3A gene. Where appropriate, it can be reasonably assumed that, based on the similarity of non-human animal and human gene sequences, they may be similarly regulated. As shown in the present application, the endogenous FCGR4 locus of a non-human animal (e.g., a mouse) comprises an inserted or replaced humanized FCGR3A, which retains the endogenous or human regulatory elements of the non-human animal, but comprises the humanization of the coding sequence, and does not exhibit pathological phenomena. Both genetically modified non-human animals that are heterozygous or homozygous for humanized FCGR3A are normal.
[0103] In some embodiments, the present invention also provides a genetically modified non-human animal, whose genome comprises a disruption of the endogenous FCGR4 gene of the non-human animal, wherein the disruption of the endogenous FCGR4 gene of the non-human animal comprises the deletion of exon 1, exon 2, exon 3, exon 4 and / or exon 5, or a partial deletion thereof.
[0104] In some embodiments, the disruption of the endogenous FCGR4 gene of the non-human animal further comprises the deletion of one or more introns selected from intron 1, intron 2, intron 3, and intron 4.
[0105] In some embodiments, the disruption of the endogenous FCGR4 gene in the non-human animal comprises a deletion of at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 650, 700, 800, 900, 1000, 12001250, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 10836, 11000, 11708, 12000, 15000, 17600, 18000 or 18472 bp nucleotides of exon 1, intron 1, exon 2, intron 2, exon 3, intron 3, exon 4, intron 4 and / or exon 5.
[0106] The genetically modified non-human animal can be various non-human animals, for example, mice, rats, rabbits, pigs, cattle (e.g., cattle, bulls, buffaloes), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., marmosets, rhesus monkeys). For non-human animals that are not easy to obtain suitable genetically modified embryonic stem cells (ES), other methods are used to construct non-human animals comprising genetic modifications. Such methods include, for example, modifying non-ES cell genomes (e.g., fibroblasts or induced pluripotent stem cells) and using nuclear transplantation to transfer the modified genome to suitable cells, such as oocytes, and incubating modified cells (e.g., modified oocytes) in non-human animals under appropriate conditions to form embryos. The above-mentioned construction methods are known in the art and are described in "A. Nagy, et al., "Manipulating the Mouse Embryo: A Laboratory Manual (Third Edition), "Cold Spring Harbor Laboratory Press, 2006", the entire contents of which are incorporated herein by reference.
[0107] In one aspect, the non-human animal is a mammal. In some embodiments, the genetically modified non-human animal is a rodent. Rodents can be selected from mice, rats and hamsters. In one embodiment, the rodent is selected from the family of Muridae. In one embodiment, the genetically modified non-human animal is from a family selected from the family of Cricetidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muroidea (true mice and rats, gerbils, spiny mice, crested rats), Malboridae (climbing mice, rock mice, tailed rats, Madagascar rats and mice), Spiny Dormouse (e.g., spiny dormouse) and Muridae (e.g., mole rats, bamboo rats and zokors). In a specific embodiment, the genetically modified rodent is selected from true mice or rats (Muroidea), gerbils, spiny mice and crested rats. In one embodiment, the genetically modified mouse is from a member of the Muridae family. In one embodiment, the non-human animal is a rodent. In a specific embodiment, the rodent is selected from mice and rats. In one embodiment, the non-human animal is a mouse.
[0108] In some embodiments, the non-human animal may be an immunodeficient non-human mammal, such as an immunodeficient rodent, an immunodeficient rabbit, an immunodeficient pig, an immunodeficient monkey, etc.
[0109] In some embodiments, the non-human animal is a mouse of the C57BL strain, wherein the C57BL strain is selected from C57BL / a, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL6, C57BL / 10, C57BL10ScSn, C57BL / 10Cr and C57BL / Ola. In some embodiments, the mouse is a 129 strain selected from 129 / J, 129 / ReJ, 129 / OlaHsd, 129 / Sv, 129 / SvJ, 129 / Re, 129 / RrJ, 129 / Sv-ter / +. These mice are described in, for example, Festing et al., Revised nomenclature for strain 129 mice, Mammalian Genome 10: 836 (1999); Auerbach et al., Establishment and Chimera Analysis of 129 / SvEv-and C57BL / 6-Derived Mouse Embryonic Stem Cell Lines (2000), the relevant contents of which are incorporated herein by reference in their entirety. In some embodiments, the genetically modified mouse is a hybrid of the 129 strain and the C57BL / 6 strain. In some embodiments, the mouse is a hybrid of the 129 strain, or a hybrid of the C57BL / 6 strain. In some embodiments, the mouse is a BALB strain, such as a BALB / c strain. In some embodiments, the mouse is a hybrid of a BALB strain and another strain. In some embodiments, the mouse is from a hybrid line (e.g., 50% BALB / c-50% 12954 / Sv; or 50% C57BL / 6-50% 129). In certain embodiments, non-human animals are rodents. In certain embodiments, non-human animals are mice with BALB / c, BALB / cHeAn, BALB / cJ, BALB / cR1, BALB / cWt, C57BL / 10, C57BL / 10ScSn, C57BL (C57BL / 10Cr and C57BL / Ola), C58, CBA / Br, CBA / Ca, CBA / J, CBA / st or CBA / H strains. In certain embodiments, non-human animals are rats. Rats can be selected from Wistar rats, LEA strains, Sprague-Dawley strains, Fischer strains, F344, F6 and Dark Agouti. In certain embodiments, rat strains are hybrid species selected from two or more strains of Wistar, LEA, Sprague-Dawley, Fischer, F344, F6 and Dark Agouti.
[0110] The present invention further relates to the FCGR3A genomic DNA sequence of humanized mice, a DNA sequence obtained by reverse transcription of mRNA that is consistent with or complementary to the DNA sequence; or a construct expressing the amino acid sequence thereof; or a cell comprising the construct thereof; or a tissue or organ comprising the cell thereof.
[0111] The present invention further relates to a non-human mammal produced by the above construction method. In some embodiments, its genome comprises a human or humanized FCGR3A gene.
[0112] In some embodiments, the non-human mammal is a rodent. In some embodiments, the non-human mammal is a mouse.
[0113] In some embodiments, the non-human mammal expresses a protein encoded by a humanized FCGR3A gene.
[0114] In addition, the present invention also provides a non-human mammal model carrying a tumor, wherein the non-human mammal model is obtained by the method described in the present application. In some embodiments, the non-human mammal is a rodent (eg, mouse).
[0115] The present invention also provides a cell or cell line derived from a non-human mammal or its offspring, or a non-human mammal carrying a tumor, or a primary cell culture, which is derived from a non-human mammal or its offspring, or a non-human mammal carrying a tumor, or a tissue, organ, or culture thereof derived from a non-human mammal or its offspring. When it carries a tumor, it is derived from a tumor tissue of a non-human mammal or its offspring, or a non-human mammal carrying a tumor.
[0116] The present invention provides a non-human mammal produced by any of the above construction methods. In some embodiments, a non-human mammal or a genetically modified non-human animal is provided, wherein the genome of the genetically modified non-human animal comprises DNA of human or humanized FCGR3A.
[0117] In some embodiments, a non-human mammal comprises a gene construct described herein (e.g., Figure 2 or Figure 7 In some embodiments, a non-human mammal expressing a human or humanized FCGR3A protein is provided. In some embodiments, a cell, tissue or organ specifically expressing a human or humanized FCGR3A protein is provided.
[0118] In some embodiments, the expression of human or humanized FCGR3A protein in the genetically modified non-human animal is controllable, such as by adding a specific inducer or repressor. In some embodiments, the specific inducer is selected from the tetracycline system (Tet-Off System / Tet-On System) or the tamoxifen system (Tamoxifen System).
[0119] The non-human mammal can be any non-human animal known in the art that can be used in the methods described herein. In some embodiments, the non-human mammal is a rodent. In some embodiments, the non-human mammal is a mouse.
[0120] The non-human mammals described above are subjected to genetic, molecular and behavioral analyses. The present invention provides offspring produced by mating with non-human mammals of the same genotype or other genotypes.
[0121] The present invention provides a cell line or primary cell culture derived from a non-human mammal or its progeny. For example, an animal model based on cell culture can be prepared by the following method. The cell culture can be obtained by isolation from a non-human mammal, or cells can be obtained from a cell culture established using the same construct and standard cell transfection techniques. The integration of a genetic construct comprising a DNA sequence encoding a human or humanized FCGR3A protein can be detected by a variety of methods.
[0122] There are many analytical methods that can be used to detect exogenous DNA, including nucleic acid level methods (including the use of reverse transcription-polymerase chain reaction (RT-PCR) or Southern Blot and in situ hybridization) and protein level methods (including histochemical analysis, immunoblot analysis and in vitro binding studies). In addition, the expression level of the target gene can be quantified by the ELSA method well known to those skilled in the art. Many standard analytical methods can be used to perform quantitative detection. For example, RT-PCR and hybridization methods can be used to detect transcription levels, including RNase protection assays, Southern Blots, and RNA dot hybridization assays (RNAdot). Immunohistochemical staining, flow cytometry, and Western blot can also be used to detect the presence of human or humanized FCGR3A protein.
[0123] In some embodiments, the genetically modified animals described herein (eg, FCGR3A gene homozygous mice) can express human or humanized FCGR3A in one or more cells.
[0124] Carrier
[0125] The present invention provides a targeting vector, comprising: a) a DNA fragment homologous to the 5' end of the conversion region to be changed (5' homology arm or 5' arm), which is selected from the genomic DNA of the FCGR4 gene and has a length of 100 to 10,000 nucleotides; b) a donor sequence; and c) a DNA fragment homologous to the 3' end of the conversion region to be changed (3' homology arm or 3' arm), which is selected from the genomic DNA of the FCGR4 gene and has a length of 100 to 10,000 nucleotides.
[0126] In some embodiments, a) the DNA fragment homologous to the 5' end of the switch region to be altered is selected from a nucleotide sequence with at least 90% identity to NCBI Accession No. NC_000067.7; c) the DNA fragment homologous to the 3' end of the switch region to be altered is selected from a nucleotide sequence with at least 90% identity to NCBI Accession No. NC_000067.7.
[0127] In some embodiments, a) a DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence at positions 170835769 to 170839730 of NCBI Accession No. NC_000067.7; c) a DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence at positions 170858203 to 170862315 of NCBI Accession No. NC_000067.7.
[0128] In some embodiments, a) the DNA fragment homologous to the 5' end of the switch region to be altered is selected from the nucleotide sequence of positions 170838843 to 170839730 of NCBI Accession No. NC_000067.7; c) the DNA fragment homologous to the 3' end of the switch region to be altered is selected from the nucleotide sequence of positions 170858203 to 170860272 of NCBI Accession No. NC_000067.7.
[0129] In some embodiments, the length of the genomic nucleotide sequence (genomic DNA) selected by the targeting vector can exceed about 0.5 kb, 0.8 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 5.8 kb, 6 kb, 8 kb, 10 kb, or 15 kb.
[0130] In some embodiments, the switch region to be changed is located on exon 1 to exon 5 of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the switch region to be changed is located on the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence of the endogenous FCGR4 gene of a non-human animal.
[0131] In some embodiments, the targeting vector further comprises one or more marker genes. For example, a resistance gene for positive clone screening or a coding gene for a negative screening marker. In some embodiments, the resistance gene for positive clone screening is a neomycin phosphotransferase coding sequence Neo. In some embodiments, the coding gene for a negative screening marker is a coding gene for a diphtheria toxin A subunit (DTA).
[0132] In some embodiments, the 5' arm is a nucleotide having at least 90% identity with NCBI Accession No. NC_000067.7, and further preferably, the 5' arm sequence comprises the nucleotide sequence shown in SEQ ID NOs: 3 and 27. In some embodiments, the 3' arm is a nucleotide having at least 90% identity with NCBI Accession No. NC_000067.7, and further preferably, the 3' arm sequence comprises the nucleotide sequence shown in SEQ ID NOs: 4 and 28.
[0133] In some embodiments, the targeting vector comprises a donor sequence, and in some embodiments, the donor sequence comprises a nucleotide sequence of human or humanized FCGR3A. For example, the donor sequence in the targeting vector comprises: a partial or complete nucleotide sequence of the human FCGR3A gene, preferably exon 1, exon 2, exon 3, exon 4, exon 5 and / or exon 6 of the human FCGR3A gene, and further preferably, a partial or complete nucleotide sequence of the endogenous FCGR4 gene of a non-human animal, preferably exon 5 of the endogenous FCGR4 gene of a non-human animal. More preferably, it further comprises a 5'UTR upstream nucleotide sequence and / or a 3'UTR downstream nucleotide sequence of the human FCGR3A gene. In some embodiments, the nucleotide sequence of human or humanized FCGR3A encodes all or part of the human FCGR3A protein, such as the protein number of NCBI NP_001121067.1 (SEQ ID NO: 2) or positions 1-229 thereof or SEQ ID NO: 35 or positions 1-229 of SEQ ID NO: 35. In some embodiments, the nucleotide sequence of human or humanized FCGR3A encodes all or part of the endogenous FCGR4 protein of a non-human animal, such as the protein number of NCBI NP_653142.2 (SEQ ID NO: 1) or positions 225-249 thereof.
[0134] In some embodiments, the targeting vector comprises, from the 5' end to the 3' end, a 5' arm, a nucleotide sequence upstream of the 5'UTR of the human FCGR3A gene to the 5' end of exon 6, a portion of exon 5 of the endogenous FCGR4 gene of a non-human animal, and a nucleotide sequence downstream of the 3' end of exon 6 to the 3'UTR of the human FCGR3A gene.
[0135] The present invention also provides a vector for constructing a humanized animal model or a knockout model. In some embodiments, the vector comprises an sgRNA sequence, wherein the sgRNA sequence targets the endogenous FCGR4 gene of a non-human animal, and the sgRNA is unique on the target sequence (target site) of the conversion region to be changed, and satisfies the sequence arrangement rule of 5'-NNN(20)-NGG3' or 5'-CCN-N(20)-3'. In some embodiments, the target site of the sgRNA in the endogenous FCGR4 gene of a non-human animal is located on exon 1, exon 2, exon 3, exon 4 and / or exon 5 of the endogenous FCGR4 gene of a non-human animal. In some embodiments, the target site of the sgRNA in the endogenous FCGR4 gene of a non-human animal is located on the 5'UTR upstream nucleotide sequence and / or the 3'UTR downstream nucleotide sequence of the endogenous FCGR4 gene of a non-human animal.
[0136] In some embodiments, the targeting sequence (target site) is shown as SEQ ID NO: 16 and 17. Therefore, the present invention provides sgRNA sequences for constructing genetically modified animal models. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 18 and 20. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 22 and 24. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 19 and 21. In some embodiments, the oligonucleotide sgRNA sequences are listed in SEQ ID NO: 23 and 25.
[0137] In some embodiments, the present disclosure relates to a plasmid construct (sgRNA vector, e.g., pT7-sgRNA) comprising an sgRNA sequence and / or a cell comprising the sgRNA vector.
[0138] The present invention also relates to a cell comprising the targeting vector or sgRNA vector.
[0139] In addition, the present invention also provides a non-human mammalian cell having any one of the above-mentioned targeting vectors and one or more in vitro transcripts of the constructs described herein (e.g., gene constructs or sgRNA vectors). In some embodiments, the cell comprises Cas9 mRNA or its in vitro transcript.
[0140] In some embodiments, the cell is heterozygous for the gene. In some embodiments, the cell is homozygous for the gene.
[0141] In some embodiments, the non-human mammalian cell is a mouse cell. In some embodiments, the cell is a fertilized egg cell. In some embodiments, the cell is an embryonic stem cell. In some embodiments, the cell can be any cell that expresses the FCGR3A protein.
[0142] Methods for constructing genetically modified non-human animals
[0143] Genetically modified non-human animals can be prepared by several gene editing techniques known in the art, including homologous recombination technology using embryonic stem cells, gene targeting technology, CRISPR / Cas9 technology, zinc finger nuclease technology, transcription activator-like effector nuclease technology, homing endonuclease or other molecular biology techniques. In some embodiments, homologous recombination technology is preferably used. In some embodiments, CRISPR / Cas9 gene editing technology can construct genetically modified non-human animals. In some embodiments, CRISPR-Cas9 genome editing is used to produce genetically modified non-human animals. Many of these genome editing technologies are known in the art and are described in Yin et al. "Delivery technologies for genome editing," Nature Reviews Drug Discovery 16.6 (2017): 387-399, which is incorporated by reference into this application. The present invention also provides many other methods for genome editing, for example, microinjecting transgenic cells into enucleated oocytes and fusing the enucleated oocytes with another transgenic cell.
[0144] In some embodiments, the nucleotide sequence encoding the endogenous FCGR4 region in the endogenous genome of at least one cell of the non-human animal is replaced by a nucleotide sequence encoding the corresponding region of human FCGR3A. In some embodiments, the nucleotide sequence encoding the extracellular region, transmembrane region and / or signal peptide of FCGR4 is replaced by a nucleotide sequence encoding the corresponding region of human FCGR3A (i.e., the human extracellular region, transmembrane region and / or signal peptide). In some embodiments, the nucleotide sequence encoding positions 1-224 of SEQ ID NO: 1 is replaced by a nucleotide sequence encoding the corresponding region of human FCGR3A (preferably positions 1-229 of SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 35). In some embodiments, the nucleotide sequence encoding SEQ ID NO: 1 is replaced by a nucleotide sequence encoding SEQ ID NO: 2. In some embodiments, the expression level of endogenous FCGR4 protein in the non-human animal is reduced or absent compared to that of wild-type animals. In some embodiments, the replacement occurs in cells such as germ cells, somatic cells, blastocysts or fibroblasts. The nucleus of a somatic cell or fibroblast can be inserted into an enucleated oocyte.
[0145] Figure 2 or Figure 7 The humanization targeting strategy of the mouse FCGR4 locus is shown. The targeting vector comprises a vector consisting of a 5' homology arm, a human or humanized FCGR3A gene (DNA and / or cDNA) fragment, and a 3' homology arm. The process involves replacing the endogenous FCGR4 sequence of a non-human animal with a human or humanized FCGR3A sequence using homologous recombination. In some embodiments, cleavage upstream and downstream of the target site (e.g., by zinc finger nucleases, TALENs, or CRISPR) can result in a double-stranded DNA break, and homologous recombination is used to replace the endogenous FCGR4 sequence of a non-human animal with a human or humanized FCGR3A sequence.
[0146] In some embodiments, the non-human animal is constructed by introducing any one or two or more of the following nucleotide sequences into the endogenous FCGR4 locus of the non-human animal:
[0147] A) a portion of the human FCGR3A gene, preferably comprising all or part of exons 1 to 6 of the human FCGR3A gene, further preferably comprising one, two or more exons of exons 1 to 6 of the human FCGR3A gene, further preferably comprising all of exon 1, exon 2, exon 3, exon 4, exon 5 and part of exon 6 of the human FCGR3A gene (preferably further comprising intron 1, intron 2 and / or intron 3 of the human FCGR3A gene), preferably further comprising the 5'UTR upstream nucleotide sequence and / or the 3'UTR downstream nucleotide sequence of the human FCGR3A gene;
[0148] B) all or part of the nucleotide sequence encoding human FCGR3A protein, preferably comprising all or part of the nucleotide sequence encoding the signal peptide, extracellular region, cytoplasmic region and / or transmembrane region of the human FCGR3A protein, further preferably comprising all or part of the nucleotide sequence encoding the signal peptide, extracellular region and / or transmembrane region of the human FCGR3A protein, more preferably comprising a nucleotide sequence encoding at least 100 consecutive amino acids in the signal peptide, extracellular region and / or transmembrane region of the human FCGR3A protein, further preferably comprising a nucleotide sequence encoding the amino acids shown in positions 1-229 of SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 35; or, comprising a nucleotide sequence encoding the amino acids shown in positions 1-229 of SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 35; a nucleotide sequence encoding an amino acid sequence having at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity to the amino acid sequence as set forth in SEQ ID NO:35 at positions 1-229; or, a nucleotide sequence encoding an amino acid sequence that differs by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or no more than 1 amino acid from the amino acid sequence as set forth in SEQ ID NO:2 at positions 1-229 or SEQ ID NO:35 at positions 1-229; or, a nucleotide sequence encoding a nucleotide sequence that comprises a substitution, deletion, and / or insertion of one or more amino acid residues from the amino acid sequence as set forth in SEQ ID NO:2 at positions 1-229 or SEQ ID NO:35 at positions 1-229;
[0149] C) a portion of an endogenous FCGR4 gene of a non-human animal, preferably comprising all or part of exons 1 to 5 of an endogenous FCGR4 gene of a non-human animal, further preferably comprising one, two or more than three exons of exons 1 to 5 of an endogenous FCGR4 gene of a non-human animal, and further preferably comprising a portion of exon 5 of an endogenous FCGR4 gene of a non-human animal;
[0150] D) all or part of the nucleotide sequence encoding the endogenous FCGR4 protein of a non-human animal, preferably comprising all or part of the nucleotide sequence encoding the signal peptide, extracellular region, cytoplasmic region and / or transmembrane region of the endogenous FCGR4 protein of a non-human animal, further preferably comprising all or part of the nucleotide sequence encoding the cytoplasmic region of the endogenous FCGR4 protein of a non-human animal, more preferably comprising a nucleotide sequence encoding at least 20 consecutive amino acids in the cytoplasmic region of the endogenous FCGR4 protein of a non-human animal, further preferably comprising a nucleotide sequence encoding the amino acids shown at positions 225-249 of SEQ ID NO:1; or, comprising a nucleotide sequence encoding amino acids having at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity with the amino acid sequence shown at positions 225-249 of SEQ ID NO:1; or, comprising a nucleotide sequence encoding amino acids having at least 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% identity with the amino acid sequence shown at positions 225-249 of SEQ ID NO:1; A nucleotide sequence that differs from the amino acid sequence set forth at positions 225-249 of SEQ ID NO:1 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 amino acid; or, a nucleotide sequence that encodes the amino acid sequence set forth at positions 225-249 of SEQ ID NO:1, including a substitution, deletion and / or insertion of one or more amino acid residues;
[0151] E) a nucleotide sequence encoding the above humanized FCGR3A protein; or,
[0152] F) The humanized FCGR3A gene described above.
[0153] Preferably, the non-human animal is constructed by introducing into the endogenous FCGR4 locus of a non-human animal a nucleotide sequence in which SEQ ID NO:5 or SEQ ID NO:5 at position 6786 is mutated from G to T, or a nucleotide sequence encoding SEQ ID NO.7 or a nucleotide sequence encoding SEQ ID NO:33; or, introducing into the endogenous FCGR4 locus of a non-human animal a nucleotide sequence comprising a nucleotide sequence having an identity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% to a nucleotide sequence in which SEQ ID NO:5 or SEQ ID NO:5 at position 6786 is mutated from G to T, or a nucleotide sequence encoding SEQ ID NO:7 or a nucleotide sequence encoding SEQ ID NO:33; or, introducing into the endogenous FCGR4 locus of a non-human animal a nucleotide sequence comprising a nucleotide sequence having an identity of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% to a nucleotide sequence in which SEQ ID NO:5 or SEQ ID NO:5 at position 6786 is mutated from G to T, or a nucleotide sequence encoding SEQ ID NO:7 or a nucleotide sequence encoding SEQ ID The construction is obtained by introducing a nucleotide sequence whose nucleotide sequence differs from that of NO:33 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or no more than 1 nucleotides into the endogenous FCGR4 locus of a non-human animal; or, the construction is obtained by introducing a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO:5 or the nucleotide sequence in which position 6786 of SEQ ID NO:5 is mutated from G to T, or the nucleotide sequence encoding SEQ ID NO:7 or the nucleotide sequence encoding SEQ ID NO:33, including substitution, deletion and / or insertion of one or more nucleotides, into the endogenous FCGR4 locus of a non-human animal.
[0154] Preferably, the non-human animal is constructed using the above-mentioned targeting vector and / or sgRNA vector.
[0155] Preferably, the non-human animal further comprises other gene modifications, more preferably, the other genes include at least one of NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA4.
[0156] Preferably, the human or humanized FCGR3A gene and / or other genes are homozygous for the endogenous modified (preferably replaced or inserted) locus.
[0157] Preferably, the human or humanized FCGR3A gene and / or other genes are heterozygous for the endogenous modified (preferably replaced or inserted) locus.
[0158] Preferably, the non-human animal can be selected from any non-human animal that can be gene-edited to prepare humanized genes, such as rodents, pigs, rabbits, monkeys, etc.
[0159] Preferably, the non-human animal is a non-human mammal. Further preferably, the non-human mammal is a rodent. Even more preferably, the rodent is a rat or a mouse.
[0160] Therefore, the present invention provides a method for constructing a non-human animal with a humanized FCGR3A gene, wherein the non-human animal expresses human or humanized FCGR3A protein in vivo, and / or the genome of the non-human animal contains a portion of the human FCGR3A gene or a humanized FCGR3A gene.
[0161] In some embodiments, the construction method includes replacing the nucleic acid sequence encoding the endogenous FCGR4 region with a nucleotide sequence encoding human or humanized FCGR3A at the endogenous FCGR4 locus (or site) of a non-human animal. Wherein, the human or humanized FCGR3A contains or does not contain a mutation, preferably, the mutation is an F176V mutation. In some embodiments, the construction method may include inserting a nucleotide sequence encoding human FCGR3A and a nucleotide sequence encoding endogenous FCGR4 of a non-human animal into the endogenous FCGR4 locus (or site) of a non-human animal. The inserted sequence may include regions (e.g., part or all of the regions) of exon 1, exon 2, exon 3, exon 4, exon 5 and / or exon 6 of the human FCGR3A gene. In some embodiments, the inserted sequence includes all of exon 1, exon 2, exon 3, exon 4, exon 5, and part of exon 6 of the human FCGR3A gene (e.g., positions 1-822 of NM_001127595.2, or a nucleotide sequence containing a mutation at position 661, preferably T or G at position 661, and positions 901-2153). In some embodiments, the inserted sequence includes part of exon 5 of the endogenous FCGR4 gene of a non-human animal (e.g., the nucleotide sequence at positions 727-804 of NM_144559.2). In some embodiments, the inserted sequence comprises a nucleotide sequence encoding a signal peptide of human FCGR3A (e.g., amino acids 1-16 of SEQ ID NO: 2), an extracellular region of human FCGR3A (e.g., amino acids 17-208 of SEQ ID NO. 2 or amino acids 17-208 of SEQ ID NO. 35), a transmembrane region of human FCGR3A (e.g., amino acids 209-229 of SEQ ID NO: 2), and a cytoplasmic region of endogenous FCGR4 of a non-human animal (e.g., amino acids 225-249 of SEQ ID NO: 1). In some embodiments, exon 1, exon 2, exon 3, exon 4, and / or exon 5 of endogenous mouse FCGR4 in an endogenous FCGR4 locus (or site) of a non-human animal are replaced. In some embodiments, the replaced sequence comprises the entire sequence from 6764 bp upstream of the 5'UTR to 872 bp downstream of the 3'UTR of the endogenous mouse FCGR4 gene.
[0162] In some embodiments, the method of modifying the FCGR4 locus of a non-human animal to express a chimeric human / non-human animal FCGR3A polypeptide may include replacing a nucleotide sequence encoding endogenous FCGR4 of a non-human animal at an endogenous FCGR4 locus of the non-human animal with a nucleotide sequence encoding human or humanized FCGR3A, thereby generating a sequence encoding a chimeric human / non-human animal FCGR3A. In some embodiments, the method may include inserting a nucleotide sequence encoding a chimeric human / non-human animal FCGR3A at an endogenous FCGR4 locus of a non-human animal, thereby generating a sequence encoding a chimeric human / non-human animal FCGR3A.
[0163] In some embodiments, the nucleotide sequence encoding the chimeric human / non-human animal FCGR3A may include a first nucleotide sequence encoding all or part of the human FCGR3A signal peptide, extracellular region and transmembrane region; and a second nucleotide sequence encoding all or part of the cytoplasmic region of the non-human animal FCGR4.
[0164] The present invention also provides a method for establishing a humanized animal model of the FCGR3A gene, comprising the following steps:
[0165] (a) providing cells (e.g., fertilized egg cells) based on the method described in the present application;
[0166] (b) culturing the cells (preferably culturing the cells in a liquid culture medium);
[0167] (c) transplanting the cultured cells into the oviduct or uterus of a recipient female non-human mammal, allowing the cells to develop in the uterus of the female non-human mammal;
[0168] (d) identifying germline transmission in offspring of the genetically modified humanized non-human mammal of the pregnant female in step (c).
[0169] In some embodiments, the non-human mammal in the above methods is a mouse (eg, a C57BL / 6 mouse).
[0170] In some embodiments, the non-human mammal in step (c) is a female with pseudopregnancy (or pregnancy).
[0171] In some embodiments, the fertilized eggs used in the above methods are C57BL / 6 fertilized eggs. Other fertilized eggs that can also be used in the methods described herein include, but are not limited to, FVB / N fertilized eggs, BALB / c fertilized eggs, DBA / 1 fertilized eggs, and DBA / 2 fertilized eggs.
[0172] The fertilized egg can be from any non-human animal, such as any non-human animal described herein. In some embodiments, the fertilized egg cell is derived from a rodent. The gene construct can be introduced into the fertilized egg by microinjection. For example, by culturing the fertilized egg after microinjection, the cultured fertilized egg can be transferred to a pseudopregnant non-human animal, and then the pseudopregnant non-human animal gives birth to a non-human mammal, thereby producing the non-human mammal mentioned in the above method.
[0173] In some embodiments, the method for preparing a genetically modified non-human animal includes modifying the coding frame of the FCGR4 gene of the non-human animal, for example, by replacing the nucleotide sequence encoding the endogenous FCGR4 region (e.g., genomic DNA, CDS sequence, or cDNA sequence) with a nucleotide sequence encoding the corresponding region of human or humanized FCGR3A under the control of the human FCGR3A gene regulatory element. For example, one or more functional region sequences of the FCGR4 gene of the non-human animal can be knocked out or inserted into a sequence so that the endogenous FCGR4 protein of the non-human animal cannot be expressed or the expression level is reduced. In some embodiments, the coding frame of the modified non-human animal FCGR4 gene can be all or part of the nucleotide sequence of exon 1, exon 2, exon 3, exon 4, and / or exon 5 of the FCGR4 gene of the non-human animal.
[0174] In some embodiments, a method for preparing a genetically modified non-human animal comprises:
[0175] (1) providing a plasmid comprising a human or humanized FCGR3A gene fragment, wherein the plasmid is flanked by a 5' homology arm and a 3' homology arm, wherein the 5' homology arm and the 3' homology arm target endogenous FCGR4 of a non-human animal;
[0176] (2) providing one or more guide RNAs (sgRNAs) targeting the endogenous FCGR4 gene;
[0177] (3) modifying the genome of a fertilized egg or embryonic stem cell by using the plasmid of step (1), the sgRNA of step (2) and Cas9;
[0178] (4) Transplanting the fertilized egg obtained in step (3) into the oviduct of a pseudo-pregnant female mouse, or transplanting the embryonic stem cells obtained in step (3) into a blastocyst, and then transplanting the blastocyst into the oviduct of a pseudo-pregnant female mouse to produce offspring mice that functionally express the humanized FCGR3A protein.
[0179] In some embodiments, the method further comprises (5) mating the offspring mice obtained in step (4) to obtain homozygous mice.
[0180] In some embodiments, the fertilized egg is modified by CRISPR with sgRNAs targeting a 5'-terminal target site and a 3'-terminal target site.
[0181] In some embodiments, the sequence encoding the humanized FCGR3A protein is operably linked to endogenous regulatory elements at the endogenous FCGR4 locus of the non-human animal.
[0182] In some embodiments, the sequence encoding the humanized FCGR3A protein is operably linked to a regulatory element of the human FCGR3A gene.
[0183] In some embodiments, the genetically modified non-human animal does not express endogenous FCGR4 protein.
[0184] In some embodiments, a method for preparing a genetically modified non-human animal comprises:
[0185] (1) providing a plasmid comprising a human or humanized FCGR3A gene fragment, wherein the plasmid is flanked by a 5' homology arm and a 3' homology arm, wherein the 5' homology arm and the 3' homology arm target endogenous FCGR4;
[0186] (2) providing one or more guide RNAs (sgRNAs) targeting the endogenous FCGR4 gene of a non-human animal;
[0187] (3) Modifying the genome of fertilized eggs or embryonic stem cells by inserting the human or humanized FCGR3A gene fragment into the endogenous FCGR4 locus of non-human animals.
[0188] In some embodiments, the construction method comprises replacing the 5'UTR upstream nucleotide sequence to the 3'UTR downstream nucleotide sequence of the non-human animal endogenous FCGR4 gene with the chimeric sequence of human FCGR3A and non-human animal endogenous FCGR4.
[0189] In some embodiments, the construction method comprises replacing a nucleotide sequence encoding an endogenous FCGR4 protein of a non-human animal in the genome of a non-human animal with a humanized FCGR3A gene or a nucleotide sequence encoding a humanized FCGR3A protein.
[0190] In some embodiments, the construction method comprises replacing the nucleotide sequence encoding SEQ ID NO: 1 in the genome of a non-human animal with a nucleotide sequence encoding SEQ ID NO: 7 or SEQ ID NO: 33.
[0191] In some embodiments, the construction method comprises replacing the nucleotide sequence encoding SEQ ID NO: 1 in the genome of a non-human animal with SEQ ID NO: 5 or a mutation at position 6786 of SEQ ID NO: 5 from G to T.
[0192] Use of genetically modified non-human animals
[0193] Replacing a non-human animal gene with a homologous or orthologous human gene or human sequence or inserting a homologous or orthologous human gene or human sequence into a non-human animal at an endogenous locus of the non-human animal and under the control of a human or endogenous regulatory element (e.g., a promoter, 5'UTR, and / or 3'UTR) can produce a non-human animal with qualities and characteristics that may be significantly different from a typical knockout plus transgenic animal. In a typical knockout plus transgenic animal, the endogenous locus is removed or destroyed, and the full human transgene is inserted into the genome of the animal and may be randomly integrated into the genome. Typically, the location of the integrated transgene is unknown; expression of the human protein is measured by transcription of a human gene and / or protein assay and / or functional assay. In a human transgene, the upstream and / or downstream of the human sequence provides suitable support for expression and / or regulation of the transgene.
[0194] The present invention demonstrates that humanized animals are produced by replacing or inserting human or humanized sequences at endogenous loci under the control of human regulatory elements, providing physiologically appropriate expression patterns and levels that are meaningful and appropriate with respect to the physiology of the replaced gene in the context of the physiology of the humanized non-human animal.
[0195] Genetically modified non-human animals or animal models that express human or humanized FCGR3A protein, e.g., in a physiologically appropriate manner, provide a variety of uses, including but not limited to developing treatments for human diseases and disorders, and evaluating the toxicity and / or efficacy of these human treatments in non-human animals or animal models.
[0196] The present invention also provides an application of the above-mentioned non-human animal comprising humanized FCGR3A gene modification, or a non-human animal obtained by any of the above-mentioned construction methods.
[0197] In some embodiments, the application comprises:
[0198] A) Application in product development involving FCGR3A-related immune processes in human cells;
[0199] B) Application as a model system related to FCGR3A for pharmacological, immunological, microbiological and medical research;
[0200] C) Applications involving the production and use of animal experimental disease models for the study of FCGR3A-related etiology and / or for the development of diagnostic strategies and / or for the development of therapeutic strategies;
[0201] D) in vivo screening, efficacy testing, efficacy assessment, validation or evaluation of human FCGR3A signaling pathway modulators; or
[0202] E) Study the function of the FCGR3A gene, study the drugs and efficacy targeting the human FCGR3A target site, and study the application of drugs in the treatment of FCGR3A-related diseases (such as tumors, inflammation, and immune diseases).
[0203] The present invention provides a non-human animal expressing human or humanized FCGR3A protein, which can be used for screening of human FCGR3A specific regulators. In some embodiments, the non-human animal is a human disease animal model. For example, the disease is genetically induced (knock-in or knock-out). In different embodiments, the genetically modified non-human animal also comprises an impaired immune system, such as a genetically modified human-derived tissue xenograft, including a human solid tumor (e.g., breast cancer) or a blood cell tumor (e.g., a lymphocyte tumor, a B or T cell tumor).
[0204] In some embodiments, the anti-FCGR3A antibodies block or inhibit the FCGR3A-mediated signaling pathway. In some embodiments, the anti-FCGR3A antibodies described herein can block the interaction between FCGR3A complexes, thereby inhibiting the FCGR3A signaling pathway.
[0205] In some embodiments, genetically modified non-human animals can be used to determine the effectiveness of therapeutic agents (e.g., anti-FCGR3A antibodies) in treating tumors. In some embodiments, a therapeutic agent (e.g., an anti-FCGR3A antibody) is administered to a non-human animal, wherein the non-human animal has a tumor, and the inhibitory effect of the therapeutic agent on the tumor is detected. In some embodiments, the detection includes determining the size and / or proliferation rate of tumor cells. In some embodiments, the detection method includes vernier caliper measurement, flow cytometry, and / or in vivo animal imaging detection. In some embodiments, the detection includes assessing individual body weight, fat mass, activation pathways, neuroprotective activity, or metabolic changes, including changes in food consumption or water consumption.
[0206] In some embodiments, the tumor cells include one or more cancer cells injected into an animal (e.g., cancer cells derived from a human or non-human animal). In some embodiments, the therapeutic agent inhibits the FCGR3A signaling pathway. In some embodiments, the therapeutic agent does not inhibit the FCGR3A signaling pathway.
[0207] In some embodiments, genetically modified non-human animals can be used to detect whether an anti-FCGR3A antibody is an agonist or antagonist. In some embodiments, the methods described herein can be used to detect the function of a therapeutic agent (e.g., an anti-FCGR3A antibody), for example, whether the therapeutic agent can upregulate an immune response or downregulate an immune response, and / or whether the therapeutic agent can induce complement-mediated cytotoxicity (CMC) or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, genetically modified non-human animals can be used to determine the effective dose of a therapeutic agent for treating a disease in a subject (e.g., a tumor, inflammation, or an immune disease). The inhibitory effect on tumors can also be determined by methods known in the art, for example, measuring tumor volume in non-human animals, and / or determining the tumor (volume) inhibition rate (TGI). TV ). The tumor growth inhibition rate can be calculated using the formula TGI TV (%) = (1-T Vt / T Vc )x100, where T Vt and T Vc is the average tumor volume (or weight) of the treatment group and the control group.
[0208] In some embodiments, therapeutic agents (e.g., anti-FCGR3A antibodies) can be used to treat various tumors. The "tumor" of the present invention refers to cells with autonomous growth ability, that is, an abnormal state or condition characterized by rapid cell growth and proliferation. The term is intended to include all types of cancerous growth or carcinogenic processes, metastatic tissues or malignantly transformed cells, tissues or organs, regardless of the histopathological type or invasive stage. The "tumor" of the present invention includes, but is not limited to, skin cancer, lymphoma, non-small cell lung cancer, cervical cancer, leukemia, ovarian cancer, nasopharyngeal cancer, breast cancer, endometrial cancer, colon cancer, rectal cancer, gastric cancer, bladder cancer, brain glioma, lung cancer, bronchial cancer, bone cancer, prostate cancer, pancreatic cancer, liver and bile duct cancer, esophageal cancer, kidney cancer, thyroid cancer, head and neck cancer, testicular cancer, glioblastoma, astrocytoma, melanoma, myelodysplastic syndrome, and sarcoma. Wherein, the leukemia is selected from acute lymphocytic (lymphoblastic) leukemia, acute myeloid leukemia, myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, plasma cell leukemia, and chronic myeloid leukemia; the lymphoma is selected from Hodgkin's lymphoma and non-Hodgkin's lymphoma, including B-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone B-cell lymphoma, T-cell lymphoma, and Waldenstrom's macroglobulinemia; the sarcoma is selected from osteosarcoma, Ewing's sarcoma, leiomyosarcoma, synovial sarcoma, soft tissue sarcoma, angiosarcoma, liposarcoma, fibrosarcoma, rhabdomyosarcoma, and chondrosarcoma. In a specific embodiment of the present invention, the tumor is breast cancer, pancreatic cancer, endocrine cancer, head and neck cancer, gastrointestinal cancer, colorectal cancer, bladder cancer, non-small cell lung cancer, glioblastoma, prostate cancer, neuroendocrine tumor, mesothelial tumor, oropharyngeal tumor, female reproductive system cancer or meningioma.
[0209] In some embodiments, therapeutic agents (e.g., antibodies targeting FCGR3A; or drugs targeting the FCGR3A signaling pathway) are designed to treat various immune diseases, including rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus, or scleroderma. Therefore, the methods described herein can be used to determine the effectiveness of therapeutic agents (e.g., antibodies targeting FCGR3A; or drugs targeting the FCGR3A signaling pathway) in suppressing immune responses. In some embodiments, the immune diseases described herein include one or more of AIDS, osteoporosis, myasthenia gravis, graft-versus-host disease (GVHD), psoriasis, allergies, asthma, myocarditis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune liver disease, pain, or neurological diseases.
[0210] In some embodiments, therapeutic agents (e.g., antibodies targeting FCGR3A; or drugs targeting the FCGR3A signaling pathway) are designed to treat various inflammations, such as viral inflammation. In some embodiments, the inflammation described herein includes acute inflammation and chronic inflammation. Specifically, inflammation includes, but is not limited to, one or more of degenerative inflammation, exudative inflammation (e.g., serous inflammation, fibrin inflammation, suppurative inflammation, hemorrhagic inflammation, necrotic inflammation, catarrhal inflammation), proliferative inflammation, specific inflammation (e.g., tuberculosis, syphilis, leprosy, or lymphogranuloma), or inflammatory bowel disease. In some embodiments, the inflammation described herein includes infection, and infection refers to local tissue and systemic inflammatory responses caused by bacteria, viruses, fungi, parasites, and / or other pathogens that invade the human body.
[0211] The present invention also provides a detection method for determining the toxicity of a therapeutic agent (e.g., an anti-FCGR3A antibody). The method comprises administering a therapeutic agent to the non-human animal described above, evaluating the weight change or blood test of the non-human animal, preferably, the blood test comprises one or more of red blood cell count, hematocrit, or hemoglobin. In some embodiments, the antibody can reduce red blood cells (RBC), hematocrit, or hemoglobin by 20%, 30%, 40%, or more than 50%. In some embodiments, the body weight of the non-human animal is at least 5%, 10%, 20%, 30%, or 40% less than that of a control group (e.g., the average body weight of a non-human animal not treated with the antibody).
[0212] The present invention also provides a non-human animal or animal model obtained by the construction method described in the present application for developing products related to human cellular immune processes, producing human antibodies, or a model system for pharmacology, immunology, microbiology and medical research.
[0213] In some embodiments, a non-human animal or animal model obtained by the construction method described in the present application is provided for producing and utilizing animal experimental disease models of immune processes of human cells, studying pathogens, or formulating new diagnostic strategies and / or therapeutic strategies.
[0214] The present invention also provides non-human animals or animal models obtained by the construction method described in the present application to screen, verify, evaluate or study the FCGR3A gene function, human FCGR3A antibodies, drugs targeting human FCGR3A or their effectiveness, such as drugs for treating immune diseases, tumors or inflammation.
[0215] In some embodiments, the present disclosure provides a method for verifying the in vivo efficacy of TCR-T, CAR-T and / or other immunotherapies (e.g., T cell adoptive transfer therapy). For example, the method includes transplanting human tumor cells into non-human animals described in the present application, and applying human CAR-T to communicating animals with human tumor cells. The effectiveness of CAR-T treatment can be determined and evaluated. In some embodiments, the communicating animal is selected from a non-human animal with a FCGR3A gene prepared by the construction method described in the present application, a double-gene or multi-gene humanized non-human animal (or its offspring) produced by the method described in the present application, a non-human animal expressing a human or humanized FCGR3A protein, or a tumor-bearing or inflammatory animal model described in the present application. In some embodiments, TCR-T, CAR-T and / or other immunotherapies can treat FCGR3A-related diseases. In some embodiments, TCA-T, CAR-T and / or other immunotherapies provide an evaluation method for treating FCGR3A-related diseases.
[0216] Non-human animal models with two or more human or humanized genes
[0217] The present invention also provides a transgenic animal model or non-human animal having two or more human or humanized genes. The non-human animal or animal model may contain a human or humanized FCGR3A gene and a sequence encoding an additional human or humanized protein.
[0218] In some embodiments, the additional human or humanized gene comprises at least one of NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA4. In some embodiments, the non-human animal or animal model also expresses at least one of human or humanized NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA4 proteins.
[0219] The present invention also provides a method for constructing two or more non-human animals or animal models with human or humanized genes, the method comprising:
[0220] (1) Providing the above-mentioned construction method to obtain non-human animals or animal models;
[0221] (ii) mating, in vitro fertilization, or direct gene editing of the non-human animal or animal model provided in step (i) with other genetically modified non-human animals, and screening to obtain multi-gene modified non-human animals.
[0222] In some embodiments, the other genetically modified non-human animals include non-human animals humanized with one or a combination of two or more of the genes NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA4.
[0223] In some embodiments, FCGR3A humanization is performed directly on a non-human animal having at least one genetic modification of human or humanized NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1, or CTLA4.
[0224] Since these proteins may involve different mechanisms, a combination therapy targeting two or more of these proteins may be a more effective treatment method. In fact, many related clinical trials are underway and have shown good results. Multigene modified non-human animal models can be used to determine the effectiveness of a combination therapy targeting two or more proteins, for example, an anti-FCGR3A antibody, and an additional therapeutic agent for treating a tumor, inflammation or immune disease (e.g., asthma or atopic dermatitis). The combination therapy method includes administering an anti-FCGR3A antibody and an additional therapeutic agent to a non-human animal, wherein the non-human animal suffers from a disease, and determining the effect of the combination therapy method on immune tumors, inflammation or immune diseases. In some embodiments, the additional therapeutic agent is an antibody that specifically binds to at least one of NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA4. In some embodiments, the additional therapeutic agent is an anti-CTLA4 antibody (e.g., ipilimumab), an anti-PD-1 antibody (e.g., nivolumab), or an anti-PD-L1 antibody. In some embodiments, the non-human animal described above further comprises a sequence encoding human or humanized PD-1, a sequence encoding human or humanized PD-L1, or a sequence encoding human or humanized CTLA-4. In some embodiments, the additional therapeutic agent is an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab), an anti-PD-L1 antibody, or an anti-CTLA-4 antibody. In some embodiments, the tumor described above comprises one or more tumor cells expressing PD-L1 and / or PD-L2.
[0225] In some embodiments, the combined treatment method is used to treat various tumors described herein, for example, solid tumors, digestive tract cancer, melanoma, gastric cancer, endometrial cancer, intestinal cancer, lymphoma, breast cancer, endocrine cancer, lung cancer, kidney cancer, multiple myeloma, non-Hodgkin's lymphoma, pancreatic cancer or ovarian cancer. One or more of the above. In some embodiments, the combined treatment method is designed to treat immune disorders described herein, such as psoriasis.
[0226] In some embodiments, the method described in the present application can be used to evaluate the combined treatment method with some other methods. The combined treatment method for treating cancer that can be used alone or in combination with the method described in the present application includes, for example, treating the subject with chemotherapy, for example, camphor alkali, doxorubicin, cisplatin, carboplatin, procarbazine, methylclorazepam, cyclophosphamide, doxorubicin, ifosfamide, melphalan, chlorbutiazine, bithiofen, nitrosourea, dacrynic acid, daunorubicin, bleomycin, primycin, mitomycin, etoposide, verapamil, podophyllotoxin, tamoxifen, paclitaxel, transplatin, 5-fluorouric acid, vincristine, vinblastine and / or methotrexate. Alternatively, in addition, the combined treatment method can include surgery on the subject to remove at least a portion of the tumor, for example, removing part or all of the tumor from the patient. BRIEF DESCRIPTION OF THE DRAWINGS
[0227] Figure 1 : Schematic diagram comparing the mouse FCGR4 locus and the human FCGR3A locus (not to scale);
[0228] Figure 2 : Schematic diagram of FCGR3A gene targeting strategy and targeting vector V1 design (not to scale);
[0229] Figure 3 :The Southern blot identification results of the F1 generation of FCGR3A gene humanized mice, where WT is the wild-type control;
[0230] Figure 4 :Flow cytometry results of the proportions of leukocyte subsets and T cell subsets in the spleen of C57BL / 6 wild-type mice (+ / +) and FCGR3A gene homozygous mice (H / H);
[0231] Figure 5 :Flow cytometry results of the proportions of leukocyte subsets and T cell subsets in the blood (peripheral blood) of C57BL / 6 wild-type mice (+ / +) and FCGR3A gene homozygous mice (H / H);
[0232] Figure 6:Flow cytometry results of the proportions of leukocyte subsets and T cell subsets in lymph nodes of C57BL / 6 wild-type mice (+ / +) and FCGR3A gene homozygous mice (H / H);
[0233] Figure 7 : Schematic diagram of FCGR3A gene targeting strategy and targeting vector V2 design (not to scale);
[0234] Figure 8 : Results of B cell clearance efficiency in C57BL / 6 wild-type mice (groups G1, G2, and G3) and FCGR3A gene humanized homozygous mice (groups G4, G5, and G6). DETAILED DESCRIPTION
[0235] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0236] In each of the following examples, equipment and materials were obtained from the following companies:
[0237] C57BL / 6 mice and Flp transgenic mice were purchased from the National Rodent Laboratory Animal Seed Center, China Food and Drug Inspection Institutes;
[0238] NsiI was purchased from NEB, catalog number R3127S;
[0239] AleI was purchased from NEB, product number R0685S; BrilliantViolet 510 TM Anti-mouse CD45 Antibody was purchased from Biolegend, catalog number: 103138;
[0240] FITC anti-Mouse CD19 Antibody was purchased from Biolegend, catalog number: 115506;
[0241] APC anti-human CD16Antibody was purchased from Biolegend, catalog number: 360705;
[0242] Purified anti-mouse CD16 / 32Antibody was purchased from Biolegend, catalog number: 101302;
[0243] Zombie NIRTM Fixable Viability Kit was purchased from Biolegend, catalog number: 423106;
[0244] Brilliant Violet 510 TM Anti-mouse CD4 Antibody was purchased from Biolegend, catalog number: 100559;
[0245] Brilliant Violet 421 TM Anti-mouse NK-1.1 Antibody was purchased from Biolegend, catalog number: 108732;
[0246] BrilliantViolet 711 TM Anti-mouseCD11cAntibody was purchased from Biolegend with the catalog number: 117349.
[0247] Example 1 FCGR3A gene humanized mice
[0248] A schematic diagram of the comparison between the mouse FCGR4 gene (NCBI Gene ID: 246256, UniProt ID: A0A0B4J1G0, located at positions 170846495 to 170857330 of chromosome 1 NC_000067.7, based on transcript NM_144559.2 and its encoded protein NP_653142.2 (SEQ ID NO: 1)) and the human FCGR3A gene (NCBI Gene ID: 2214, UniProt ID: P08637, located at positions 161541759 to 161550737 of chromosome 1 NC_000001.11, based on transcript NM_001127595.2 and its encoded protein NP_001121067.1 (SEQ ID NO: 2)) is shown in FIG. Figure 1 shown.
[0249] In order to achieve the purpose of the present invention, a nucleotide sequence encoding a chimeric protein (humanized FCGR3A protein) of human FCGR3A and mouse endogenous FCGR4 can be introduced into the mouse endogenous FCGR4 locus, so that the mouse expresses human or humanized FCGR3A protein. Specifically, using gene editing technology, a chimeric nucleotide sequence fragment comprising a nucleotide sequence encoding human FCGR3A protein and encoding mouse FCGR4 protein (comprising a nucleotide sequence from the upstream nucleotide sequence of the 5'UTR of the human FCGR3A gene to the 5' end of exon 6, a part of exon 5 of the mouse endogenous FCGR4 gene, and a nucleotide sequence from the 3' end of exon 6 of the human FCGR3A gene to the downstream nucleotide sequence of the 3'UTR) of about 14kb is used to replace a nucleotide sequence from the upstream nucleotide sequence of the mouse 5'UTR to the downstream nucleotide sequence of the 3'UTR, which is about 18.5kb. The chimeric sequence is controlled by the human FCGR3A gene regulatory element to obtain a humanized FCGR3A locus, thereby realizing the humanization of the mouse FCGR4 gene.
[0250] Design as Figure 2 The targeting strategy shown, Figure 2 The targeting vector V1 contains homology arm sequences upstream and downstream of the mouse FCGR4 gene, and A fragment SEQ ID NO: 5, which contains the upstream nucleotide sequence of the 5'UTR of the human FCGR3A gene, the partial nucleotide sequence encoding the human FCGR3A protein, the partial nucleotide sequence encoding the mouse FCGR4 protein, and the nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene. Among them, the upstream 5' homology arm sequence (SEQ ID NO: 3) is identical to the nucleotide sequence of positions 170835769 to 170839730 of the NCBI accession number NC_000067.7, and the downstream 3' homology arm sequence (SEQ ID NO: 4) is identical to the nucleotide sequence of positions 170858203 to 170862315 of the NCBI accession number NC_000067.7. The connection design of the upstream of the A fragment sequence and the mouse is:
[0251] AG-3' (SEQ ID NO: 8), wherein the sequence " TGTAA The last "A" in the sequence is the last nucleotide of the mouse sequence. The first "G" in is the first nucleotide of segment A. The connection between the mouse coding sequence upstream and the human coding sequence in segment A is designed as: The sequence " CTGTG The last "G" in the sequence is the last nucleotide of the human coding sequence. The "C" in the A fragment is the first nucleotide of the mouse coding sequence. The connection between the mouse coding sequence downstream and the human sequence in the A fragment is designed as follows:
[0252] The sequence " AGTGA The last "A" in the " is the last nucleotide of the mouse coding sequence. The first "C" in is the first nucleotide of the human sequence.
[0253] The targeting vector also includes a resistance gene for positive clone screening, namely the neomycin phosphotransferase coding sequence Neo, and two site-specific recombination system Frt recombination sites arranged in the same direction are installed on both sides of the resistance gene to form a Neo cassette. The connection between the 5' end of the Neo cassette and the A fragment is designed as follows: The sequence " GAGAG The last "G" in the sequence is the last nucleotide of the A segment. The first "G" in is the first nucleotide of the Neo box; the connection between the 3' end of the Neo box and the mouse FCGR4 gene is designed as: The sequence " ACTTC The last "C" in the sequence is the last nucleotide of the Neo box. The first "T" in is the first nucleotide of the mouse FCGR4 gene. The mRNA sequence transcribed from the humanized FCGR3A gene in the transformed mouse is shown in SEQ ID NO: 6, and the expressed protein sequence is shown in SEQ ID NO: 7, and subsequent verification is performed.
[0254] Similar to the above method, the A fragment is SEQ ID NO: 5, where the 6786th position is mutated from G to T, and the rest is consistent with the targeting vector V1. The mRNA sequence transcribed from the humanized FCGR3A gene in the transformed mice is shown in SEQ ID NO. 34, and the expressed protein sequence is shown in SEQ ID NO: 33.
[0255] The construction of the targeting vector can be carried out by conventional methods, such as enzyme digestion and ligation. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector verified by sequencing is electroporated and transfected into the embryonic stem cells of C57BL / 6 mice, and the obtained cells are screened using the positive clone screening marker gene to screen the correct positive clone cells. The screened correct positive clone cells (black mice) are introduced into the separated blastocysts (white mice) according to the technology known in the art, and the obtained chimeric blastocysts are transferred to the culture medium for short-term culture and then transplanted into the oviduct of the recipient mother mouse (white mouse), and F0 generation chimeric mice (black and white) can be produced. F0 generation chimeric mice are backcrossed with wild-type mice to obtain F1 generation mice, and then F1 generation heterozygous mice are mated with each other to obtain F2 generation homozygous mice. Positive mice can also be mated with F1p tool mice to remove the positive clone screening marker gene, and then mated with each other to obtain FCGR3A gene humanized homozygous mice.
[0256] In addition, CRISPR / Cas9 technology can be used for gene editing to further design Figure 7 The targeting strategy shown, Figure 7 The homology arm sequences upstream and downstream of the mouse FCGR4 gene on the targeting vector V2 are shown, as well as the A fragment SEQ ID NO: 5 (comprising the 5'UTR upstream nucleotide sequence of the human FCGR3A gene, all of exon 1, exon 2, exon 3, exon 4, and exon 5 of the human FCGR3A gene, the 5' end of exon 6 of the human FCGR3A gene, part of exon 5 of the mouse FCGR4 gene, the 3' end of exon 6 of the human FCGR3A gene, and the 3'UTR downstream nucleotide sequence of the human FCGR3A gene). Among them, the upstream 5' homology arm sequence (SEQ ID NO: 27) is identical to the nucleotide sequence of positions 170838843 to 170839730 of NCBI accession number NC_000067.7, and the downstream 3' homology arm sequence (SEQ ID NO: 28) is identical to the nucleotide sequence of positions 170858203 to 170860272 of NCBI accession number NC_000067.7. The connection design of the upstream of the A fragment sequence and the mouse is: The sequence " TGTAA The last "A" in the sequence is the last nucleotide of the mouse sequence. The first "G" in is the first nucleotide of segment A. The downstream connection of segment A sequence to mouse is designed as:
[0257] The sequence " GAGAG The last "G" in the sequence is the last nucleotide of the A segment. The first "T" in is the first nucleotide of the mouse sequence. The mRNA sequence transcribed from the humanized FCGR3A gene in the transformed mouse is shown in SEQ ID NO: 6, and the expressed protein sequence is shown in SEQ ID NO: 7.
[0258] Similar to the above method, the A fragment is SEQ ID NO: 5, where the 6786th position is mutated from G to T, and the rest is consistent with the targeting vector V2. The mRNA sequence transcribed from the humanized FCGR3A gene in the transformed mice is shown in SEQ ID NO: 34, and the expressed protein sequence is shown in SEQ ID NO: 33.
[0259] Conventional methods can be used to construct the targeting vector, such as enzyme digestion, ligation, direct synthesis, etc. After the constructed targeting vector is initially verified by enzyme digestion, it is sent to a sequencing company for sequencing verification. The targeting vector that is verified to be correct by sequencing is used for subsequent experiments.
[0260] The target sequence determines the targeting specificity of sgRNA and the efficiency of inducing Cas9 to cut the target gene. Therefore, efficient and specific target sequence selection and design are the prerequisites for constructing sgRNA expression vectors. Design and synthesize sgRNA sequences that recognize target sites. The target sequence of the exemplary sgRNA on the FCGR4 gene is as follows:
[0261] sgRNA1 target site (SEQ ID NO: 16): 5'-TGACCCTTGGAAGGCCGATCAGG-3';
[0262] sgRNA2 target site (SEQ ID NO: 17): 5′-AGTGGAGTTTGCACTCTCTAGGG-3′;
[0263] The activity of sgRNA was detected by UCA kit. After confirming that it could mediate efficient cutting efficiency, restriction sites were added to its 5' end and complementary chain to obtain forward oligonucleotide and reverse oligonucleotide sequences as shown in Table 3. After annealing, the annealing products were connected to pT7-sgRNA plasmid (the plasmid was linearized with BbsI first) to obtain expression vectors pT7-FCGR4-1 and pT7-FCGR4-2.
[0264] Table 3 sgRNA1 and sgRNA2 sequence list
[0265]
[0266]
[0267] The pT7-sgRNA vector was synthesized by a plasmid synthesis company with a fragment DNA containing a T7 promoter and sgRNA scaffold (SEQ ID NO: 26) and connected to a backbone vector (source: Takara, item number 3299) by restriction digestion (EcoRI and BamHI) in sequence. The vector was sequenced and verified by a professional sequencing company, and the results showed that the target plasmid was obtained. Take a mouse pronuclear fertilized egg, such as a C57BL / 6 mouse, and use a microinjector to pre-mix the in vitro transcription products of pT7-FCGR4-1 and pT7-FCGR4-2 plasmids (using the Ambion in vitro transcription kit, according to the instructions for transcription), the targeting vector and Cas9 mRNA and inject them into the cytoplasm or nucleus of the mouse fertilized egg. Microinjection of fertilized eggs was performed according to the method in the "Mouse Embryo Manipulation Experiment Manual (3rd Edition)" (Andras Nagy, Chemical Industry Press, 2006). The injected fertilized eggs were transferred to culture medium for short-term culture and then transplanted into the oviduct of the recipient mother mouse for development. The obtained mice (F0 generation) were hybridized and self-fertilized to expand the population and establish a stable FCGR3A gene humanized mouse strain.
[0268] The PCR method can be used to identify the somatic cell genotype of F1 generation mice, and the F1 generation PCR-positive mice are subjected to Southern blot detection to confirm whether there is random insertion. The mouse tail is cut to extract genomic DNA, and the genome is digested with AleI enzyme or NsiI enzyme, transferred to a membrane, and hybridized. The 3' probe (3'Probe) and the 5' probe (AProbe) are located on the 3' homology arm and on the A fragment, respectively. The specific probe and target fragment length are shown in Table 4 below, and the exemplary results are shown in Table 4 below. Figure 3 As shown, combined with the PCR and sequencing results, four mice numbered F1-04 to F1-07 were positive mice. This indicates that the present method can be used to construct FCGR3A gene humanized mice that can be stably propagated and have no random insertions.
[0269] Table 4 Length of specific probes and target fragments
[0270] Restriction enzymes Probe Wild-type fragment size Recombinant sequence fragment size AleI 3′Probe 8.3kb 15.4kb NlI AProbe - 12.2kb
[0271] AProbe-F (SEQ ID NO: 12): 5'-CCAGCTCTGCAAACATGACAGTCTA-3',
[0272] AProbe-R (SEQ ID NO: 13): 5'-CTGTAAGTCCTAGAGGATGACAA-3';
[0273] 3'Probe-F (SEQ ID NO: 14): 5'-GCCTAGTTAATTTACGTAGGCAAATGTG-3',
[0274] 3'Probe-R (SEQ ID NO: 15): 5'-GTTGACCTGTGCTTAATCTGTGTTC-3';
[0275] In addition, the expression of humanized FCGR3A (hFCGR3A) protein in FCGR3A humanized mice can be detected by conventional methods such as flow cytometry. Specifically, 8-week-old male C57BL / 6 mice (+ / +) and 8-week-old male FCGR3A homozygous humanized mice (H / H) prepared in this example were selected, and the peritoneal lavage fluid macrophages of the mice were collected after euthanasia by cervical dislocation. Brilliant Violet 510 was used to detect the expression of humanized FCGR3A (hFCGR3A) protein in FCGR3A humanized mice. TM After identification and staining with anti-mouse CD45 Antibody, FITC anti-MouseCD 19Antibody and APC anti-humanCD16Antibody, flow cytometry was performed. It was found that 93.3% of the macrophages in the ascites of wild-type mice were mFCGR4-positive cells and 0.52% of the hFCGR3A-positive cells, and 0.55% of the macrophages in the ascites of FCGR3A gene humanized homozygous mice were mFCGR4-positive cells and 99.6% of the hFCGR3A-positive cells. In summary, the FCGR3A humanized mice constructed in this example can successfully express the humanized FCGR3A protein.
[0276] Furthermore, flow cytometry was used to perform immunophenotyping on the spleen, peripheral blood, and lymph node tissues of C57BL / 6 wild-type mice and FCGR3A humanized homozygous mice. Specifically, 7-week-old male C57BL / 6 wild-type mice and 7-week-old male FCGR3A humanized homozygous mice were euthanized, and spleen, peripheral blood, and lymph node tissues were obtained. Purified anti-mouse CD16 / 32Antibody, Zombie NIR TM Fixable Viability Kit, Brilliant Violet 510 TM anti-mouse CD4 Antibody, Brilliant Violet 421 TManti-mouse NK-1.1Antibody, FITC anti-mouse CD19Antibody and BrilliantViolet 711 TM Anti-mouse CD11cAntibody and other antibodies were used for detection. The results of leukocyte subtype and T cell subtype detection in spleen were as follows: Figure 4 As shown, the results of the detection of leukocyte subtypes and T cell subtypes in peripheral blood are as follows Figure 5 As shown, from Figure 4 and 5 It can be seen that the leukocyte subtypes such as T cells, B cells, NK cells, granulocytes, DC cells, macrophages and monocytes in the spleen and peripheral blood of FCGR3A gene humanized homozygous mice are basically the same as those of C57BL / 6 wild-type mice ( Figure 4 A and Figure 5 A), the percentages of T cell subtypes such as CD4+T cells, CD8+T cells, and Tregs cells were basically the same as those of C57BL / 6 wild-type mice ( Figure 4 B and Figure 5 B).
[0277] The results of the detection of leukocyte subtypes and T cell subtypes in lymph nodes are as follows: Figure 6 As shown in the figure, it can be seen that the leukocyte subtypes such as T cells, B cells, and NK cells in the lymph nodes of FCGR3A gene humanized homozygous mice are basically the same as those of C57BL / 6 wild-type mice ( Figure 6 A), the percentages of T cell subtypes such as CD4+T cells, CD8+T cells and Tregs cells are basically consistent with those of C57BL / 6 wild-type mice ( Figure 6 B). The results showed that the humanization of FCGR3A gene did not affect the differentiation, development and distribution of leukocytes and T cells in mice.
[0278] In another experiment, peripheral blood of C57BL / 6 mice (+ / +) and FCGR3A gene humanized homozygotes (H / H) were divided into three groups, including G1, G2, and G3 for C57BL / 6 mice and G4, G5, and G6 for FCGR3A gene humanized mice, with 6 mice in each group. Groups G1 and G4 were given 200 μL of PBS, groups G2 and G5 were given 250 μg of anti-mouse CD20 antibody hIgG1anti-mCD20, and groups G3 and G6 were given 250 μg of anti-mouse CD20 antibody hIgG1-mut anti-mCD20. The difference between anti-mouse CD20 antibody hIgG1-mut anti-mCD20 and hIgG1 anti-mCD20 (heavy chain sequence is SEQ ID NO: 29, light chain sequence is SEQ ID NO: 30) is that its FC region contains the following mutations: S239D, A330L, 1332E.
[0279] Blood was collected 1 day before administration (Day-1) and on the 2nd (Day2), 4th (Day4), 7th (Day7) and 14th (Day14) days after administration to detect B cell clearance. The results showed ( Figure 8 ), in C57BL / 6 mice (+ / +) and FCGR3A gene humanized homozygous (H / H) mice, both anti-mouse CD20 antibodies showed similar B cell clearance rates, and the anti-mouse CD20 antibody hIgG1-mutanti-mCD20 (G3, G6) had a higher B cell clearance rate than hIgG1 anti-mCD20 (G2, G5). This data shows that the humanized FCGR3A gene still retains normal ADCC function.
[0280] Example 2 Model and efficacy verification
[0281] The FCGR3A humanized mice prepared by this method can be used to evaluate the efficacy of regulators targeting human FCGR3A in tumor diseases. For example, FCGR3A humanized mice homozygous for MC38 cells are subcutaneously inoculated, and the tumor volume grows to about 100 mm. 3 The mice were then divided into a control group or a treatment group according to the tumor volume. The treatment group randomly selected a drug targeting human FCGR3A, and the control group was injected with an equal volume of saline. The tumor volume was measured regularly and the mice were weighed. By comparing the weight changes of the mice and the tumor size, the in vivo safety and in vivo efficacy of the compound can be effectively evaluated.
[0282] Example 3 Preparation of double-gene or multi-gene humanized mice
[0283] The FCGR3A gene humanized mouse prepared in Example 1 of the present application can also be used to prepare a multi-gene humanized mouse model. For example, in the aforementioned Example 1, the embryonic stem cells used for microinjection can be selected from mice modified with at least one gene containing NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA4, or, based on the humanized FCGR3A mouse, a dual-gene humanized or multi-gene humanized mouse model can be obtained by isolating mouse ES embryonic stem cells and gene recombination targeting technology. The homozygous or heterozygous FCGR3A mice obtained by this method can also be mated with other gene-modified mice, and their offspring can be screened. According to Mendel's law of inheritance, there is a certain probability of obtaining multigenic mice modified with humanized FCGR3A gene and other genes, and then the heterozygotes can be mated with each other to obtain homozygous mice modified with two genes or multiple genes.
[0284] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0285] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
[0286] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.
Claims
1. A method for constructing a genetically modified non-human animal, It is characterized in that The genome of the non-human animal comprises at least one chromosome comprising a nucleotide sequence encoding a human or humanized Fcγ receptor IIIa (FCGR3A) protein.
2. The construction method according to claim 1, It is characterized in that The humanized FCGR3A protein comprises a human or humanized extracellular region, a human or humanized transmembrane region and a non-human animal cytoplasmic region.
3. The construction method according to any one of claims 1 to 2, It is characterized in that The amino acid sequence of the human or humanized FCGR3A protein comprises SEQ ID NO: 2 or positions 1-229 of SEQ ID NO: 2 or SEQ ID NO: 35 or positions 1-229 of SEQ ID NO. 35; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity with positions 1-229 of SEQ ID NO: 2 or SEQ ID NO: 2 or SEQ ID NO: 35 or SEQ ID NO:
35.
4. The construction method according to any one of claims 1 to 3, It is characterized in that The amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 1 or positions 225-249 of SEQ ID NO: 1; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity with amino acids 225-249 of SEQ ID NO: 1 or SEQ ID NO:
1.
5. The construction method according to any one of claims 1 to 4, It is characterized in that The amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 7 or SEQ ID NO: 33; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to SEQ ID NO: 7 or SEQ ID NO:
33.
6. A method for constructing a genetically modified non-human animal, It is characterized in that At the non-human animal endogenous FCGR4 gene locus, the non-human animal endogenous FCGR4 gene is replaced with a nucleotide sequence comprising human or humanized FCGR3A.
7. The construction method according to claim 6, It is characterized in that The nucleotide sequence of the humanized FCGR3A comprises a portion of the human FCGR3A gene; Preferably, the portion of the human FCGR3A gene comprises all of exon 1, exon 2, exon 3, exon 4, exon 5 and / or a portion of exon 6 of the human FCGR3A gene. Preferably, the portion of exon 6 of the human FCGR3A gene comprises at least 5 bp of continuous nucleotide sequence at the 5' end and / or at least 5 bp of continuous nucleotide sequence at the 3' end of exon 6; Preferably, the portion of the human FCGR3A gene comprises at least 50 bp of continuous nucleotide sequence upstream of the 5'UTR and / or at least 50 bp of continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene; Further preferably, the portion of the human FCGR3A gene comprises at least 50 bp of continuous nucleotide sequence upstream of the 5'UTR of the human FCGR3A gene to at least 5 bp of continuous nucleotide sequence at the 5' end of exon 6, and at least 5 bp of continuous nucleotide sequence at the 3' end of exon 6 to at least 50 bp of continuous nucleotide sequence downstream of the 3'UTR of the human FCGR3A gene; Preferably, the portion of the human FCGR3A gene comprises intron 1, intron 2 and / or intron 3 of the human FCGR3A gene.
8. The construction method according to claim 7, It is characterized in that The nucleotide sequence of the humanized FCGR3A also includes a portion of the endogenous FCGR4 gene of a non-human animal; Preferably, the portion of the endogenous FCGR4 gene of the non-human animal comprises a portion of exon 5 of the endogenous FCGR4 gene of the non-human animal; preferably, the portion of exon 5 of the endogenous FCGR4 gene of the non-human animal comprises at least 5 bp of continuous nucleotide sequence.
9. The construction method according to any one of claims 6 to 8, It is characterized in that The nucleotide sequence of the humanized FCGR3A comprises SEQ ID NO: 5 or SEQ ID NO: 5 at position 6786 where G is mutated to T, or comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 5 or SEQ ID NO: 5 at position 6786 where G is mutated to T.
10. The construction method according to any one of claims 6 to 9, It is characterized in that All of exons 1-5 of the endogenous FCGR4 gene of non-human animals are replaced; Preferably, the replaced endogenous FCGR4 gene of the non-human animal further comprises at least 50 bp of continuous nucleotide sequence upstream of the 5'UTR and / or at least 50 bp of continuous nucleotide sequence downstream of the 3'UTR of the endogenous FCGR4 gene of the non-human animal.
11. The construction method according to claims 1-10, It is characterized in that The expression of the nucleotide sequence encoding human or humanized FCGR3A protein or the nucleotide sequence of human or humanized FCGR3A is regulated by a regulatory element, and the regulatory element is preferably a regulatory element of human FCGR3A and / or a regulatory element of non-human animal FCGR4; Preferably, the endogenous FCGR4 protein in the non-human animal is not expressed or is expressed at a reduced level compared to FCGR4 in wild-type animals; Preferably, the modified FCGR3A gene in the genome of the non-human animal is homozygous or heterozygous for the endogenous replaced locus.
12. The construction method according to any one of claims 1 to 11, It is characterized in that The non-human animals include mammals, such as monkeys or rodents, and preferably, the rodents include mice or rats.
13. The construction method according to any one of claims 1 to 12, It is characterized in that The mRNA transcribed from the modified FCGR3A gene in the genome of the non-human animal comprises SEQ ID NO: 6 or SEQ ID NO: 34, or comprises a nucleotide sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the nucleotide sequence shown in SEQ ID NO: 6 or SEQ ID NO:
34.
14. The construction method according to any one of claims 1 to 13, It is characterized in that The non-human animal also includes nucleotide sequences of human or humanized proteins encoded by other genes, and the human or humanized proteins include at least one of NKP46, CD3E, EGFR, CCR8, NKG2D, CD32, CD64, LAG3, 4-1BB, CD40, TIGIT, CD27, CD28, B7H3, OX40, PD-1, PD-L1 or CTLA4.
15. A method for determining the effectiveness of a therapeutic agent in treating a disease, It is characterized in that The method comprises: 1) administering a therapeutic agent to a non-human animal obtained by the construction method according to any one of claims 1 to 14, wherein the non-human animal suffers from a disease; 2) determine the inhibitory effect of the therapeutic agent on the disease; Preferably, the therapeutic agent comprises an anti-FCGR3A antibody or an anti-CD20 antibody; Preferably, the therapeutic agent further comprises an additional therapeutic agent, such as one or more of an anti-PD-1 antibody, an anti-PD-L1 antibody or an anti-CTLA4 antibody.
16. The method according to claim 15, wherein the disease comprises a tumor, an inflammation or an immune disease; Preferably, the tumor includes one or more of solid tumors, digestive tract cancer, melanoma, gastric cancer, endometrial cancer, intestinal cancer, lymphoma, breast cancer, endocrine cancer, lung cancer, kidney cancer, multiple myeloma, non-Hodgkin's lymphoma, pancreatic cancer or ovarian cancer; Preferably, the immune disease includes one or more of AIDS, osteoporosis, myasthenia gravis, graft-versus-host disease (GVHD), psoriasis, allergy, asthma, atopic dermatitis, myocarditis, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, hyperthyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune liver disease, pain or nervous system diseases; Preferably, the inflammation includes one or more of degenerative inflammation, exudative inflammation (such as serous inflammation, fibrinous inflammation, suppurative inflammation, hemorrhagic inflammation, necrotizing inflammation, catarrhal inflammation), proliferative inflammation, specific inflammation (such as tuberculosis, syphilis, leprosy or lymphogranuloma) or inflammatory bowel disease.
17. A method for determining the toxicity of a FCGR3A therapeutic agent, It is characterized in that The method comprises: 1) administering an FCGR3A therapeutic agent to a non-human animal obtained by the construction method according to any one of claims 1 to 14; 2) Determine the effects of FCGR3A therapeutics in non-human animals; Preferably, the determining of the effect of the FCGR3A therapeutic agent on the non-human animal comprises measuring the body weight or performing a blood test on the non-human animal. Preferably, the blood test comprises one or more of red blood cell count, hematocrit or hemoglobin content.
18. A humanized FCGR3A protein, It is characterized in that The humanized FCGR3A protein comprises the transmembrane region of the human FCGR3A protein, the extracellular region of the human FCGR3A protein, and the cytoplasmic region of the endogenous FCGR4 protein of a non-human animal; Preferably, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO: 35 or SEQ ID NO: 35 positions 1-229; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity to SEQ ID NO: 2 or SEQ ID NO: 2 positions 1-229 or SEQ ID NO. 35 or SEQ ID NO: 35 positions 1-229; Preferably, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249; or comprises at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identity with SEQ ID NO: 1 or SEQ ID NO: 1, positions 225-249; Further preferably, the amino acid sequence of the humanized FCGR3A protein comprises SEQ ID NO: 7 or SEQ ID NO: 33; or comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% identical to the amino acid sequence shown in SEQ ID NO: 7 or SEQ ID NO:
33.
19. A humanized FCGR3A gene, It is characterized in that The humanized FCGR3A gene encodes the humanized FCGR3A protein according to claim 18; Preferably, the humanized FCGR3A gene comprises a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 27, 28, 29, 30 or 34, or comprises a nucleotide sequence with an identity of at least 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% to the nucleotide sequence shown in SEQ ID NO: 3, 4, 5, 6, 8, 9, 27, 28, 29, 30 or 34.
20. A cell, tissue or organ, It is characterized in that The cell, tissue or organ expresses the humanized FCGR3A protein according to claim 18, and / or the cell, tissue or organ contains the humanized FCGR3A gene according to claim 19.
21. A use of a non-human animal obtained by the construction method of any one of claims 1 to 14, the humanized FCGR3A protein of claim 18, the humanized FCGR3A gene of claim 19, or the cell, tissue or organ of claim 20, It is characterized in that The application includes: A) Application in product development involving FCGR3A-related immune processes in human cells; B) Application as a model system related to FCGR3A for pharmacological, immunological, microbiological and medical research; C) Applications involving the production and use of animal experimental disease models for the study of FCGR3A-related etiology and / or for the development of diagnostic strategies and / or for the development of therapeutic strategies; D) in vivo screening, efficacy testing, efficacy assessment, validation or evaluation of human FCGR3A signaling pathway modulators; or E) To study the function of FCGR3A gene, the drugs and their efficacy targeting human FCGR3A target sites, and the application of drugs in the treatment of FCGR3A-related diseases.
